

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young adults committing low-level offences: a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081179
Article Type:	Original research
Date Submitted by the Author:	20-Oct-2023
Complete List of Authors:	Mitchell, Alex; University of York, Department of Health Sciences Booth, Alison; University of York, UK, Department of Health Sciences Morgan, Sara; University of Southampton Walker, Inna; University of Southampton Chapman, Caroline; Hampshire Constabulary Barlow-Pay, Megan; University of Southampton Cochrane, Ann; University of York, Department of Health Sciences Filby, Emma; University of York, Department of Health Sciences Fleming, Jenny; University of Southampton Highfield Campus, Department of Sociology Hewitt, Catherine; The University of York, Health Sciences Raftery, James; Southampton University, WIHRD, School of Medicine Torgerson, David; The University of York Weir, Lana; University of Southampton Parkes, Julie; University of Southampton, Public Health Sciences and Medical Statistics
Keywords:	PUBLIC HEALTH, Adolescents < Adolescent, Randomized Controlled Trial

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young**  
4 **adults committing low-level offences: a randomised controlled trial**  
5  
6  
7

8 **Authors:** Alex Mitchell<sup>1</sup>, Alison Booth<sup>1</sup>, Sara Morgan<sup>2</sup>, Inna Walker<sup>2</sup>, Caroline Chapman<sup>3</sup>, Megan  
9 Barlow-Pay<sup>2</sup>, Ann Cochrane<sup>1</sup>, Emma Filby<sup>1</sup>, Jenny Fleming<sup>4</sup>, Catherine Hewitt<sup>1</sup>, James Raftery<sup>2</sup>, David  
10 J. Torgerson<sup>1</sup>, Lana Weir<sup>2</sup>, Julie Parkes<sup>2</sup>  
11  
12  
13  
14

- 15  
16 1. York Trials Unit, Department of Health Sciences, Faculty of Sciences, University of York, York,  
17 UK  
18  
19 2. School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine,  
20 University of Southampton, Southampton, UK  
21  
22 3. Southampton Central Police Station, Hampshire Constabulary, Southampton, UK  
23  
24 4. Department of Sociology, Social Policy and Criminology, Faculty of Social Sciences, University  
25 of Southampton Highfield Campus, Southampton, UK  
26  
27  
28  
29  
30  
31

32 **Corresponding author:** Alex Mitchell, York Trials Unit, Department of Health Sciences, University of  
33 York, York, UK; [alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Background:** Young adults who commit low-level offences commonly have a range of health and social needs and are significantly over-represented in the criminal justice system. These young adults may need to attend court and potentially receive penalties including imprisonment. Alternative routes exist, which can help address the underlying causes of offending. Some feel more should be done to help young adults entering the criminal justice system. The Gateway programme was a type of out-of-court disposal (OOC) developed by Hampshire Constabulary, which aimed to address the complex needs of young adults who commit low-level crimes. This study aimed to evaluate the effectiveness and cost-effectiveness of the Gateway programme, issued as a conditional caution, compared to usual process.

**Methods:** The Gateway study was a pragmatic, parallel-group, superiority randomised controlled trial (RCT) that recruited young adults who had committed a low-level offence from four sites covering Hampshire and Isle of Wight. The primary outcome was mental health and wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcomes were quality of life, alcohol and drug use, and recidivism. Outcomes were measured at 4, 16 and 52 weeks post-randomisation.

**Results:** Due to issues with retention of participants and low data collection rates, recruitment ended early, with 191 eligible participants randomised (Gateway 109; usual process 82). The primary outcome was obtained for 93 (48.7%) participants at 4 weeks, 93 (48.7%) at 16 weeks and 43 (22.5%) at 1 year.

**Conclusions:** Gateway is the first trial in a UK police setting to have a health-related primary outcome requiring individual data collection, rather than focusing solely on recidivism. We demonstrated that it is possible to recruit and randomise from the study population, however follow-up rates were low. Further work is needed to identify ways to facilitate engagement between researchers and vulnerable populations to collect data.

1  
2  
3 **Trial registration:** ISRCTN11888938  
4  
5

6 **Keywords:** young adults; criminal justice; recidivism; police; vulnerable populations  
7  
8

9 **Word count:** 4568  
10  
11

### 12 **Strengths and limitations of this study**

13

- 14 • The Gateway study is the first RCT in the UK police setting to have a health-related primary  
15 outcome requiring individual data collection rather than prioritising criminal justice data on  
16 recidivism.  
17  
18
- 19 • Using a novel two-stage consent process, we demonstrated that is possible to recruit and  
20 randomise young people who have committed a minor offence to an RCT in the police  
21 setting.  
22  
23
- 24 • The study was an example of close collaboration between the research team and police  
25 partners.  
26  
27
- 28 • Due to high attrition rates, the study was ended early and an assessment of the  
29 effectiveness of the Gateway intervention compared to usual process could not be  
30 completed.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Background

Young adults who commit low-level offences commonly have a range of health and social needs, making them vulnerable to mental health problems. (1, 2) These young adults are more likely to come into contact with the police both as suspects and victims of crime and are significantly over-represented in the criminal justice system, accounting for approximately one third of police, probation and prison caseloads. (3) According to statistics from Hampshire Constabulary (HC) for 2018/20, the five main low-level offence categories for adults aged between 18 and 24 where formal action was taken by the police are possession of drugs, violence, shoplifting, criminal damage and public order offences. Young adults who have been investigated for a suspected low-level offence, may need to attend court and, if convicted, face penalties such as prison.

More could be done to help young adults entering the criminal justice system, for example via court diversion programmes. Diversion is a process whereby an accused person is formally moved into a programme in the community, such as an out-of-court community-based intervention (OCBI), instead of entering the criminal justice system. (4) In the UK, a number of police forces are exploring the use of out-of-court disposals amongst 18–24-year-olds involved in less serious offending. (5, 6) The aim is to divert the young adult away from their offending behaviour. (7)

The Gateway programme was a novel form of conditional caution, conceived by HC as a culture-changing initiative that sought to address the complex needs of adults aged 18-24 years who commit low-level crimes. However, HC recognised the lack of evidence on the effectiveness of Gateway and were keen on an evaluation of its effectiveness in relation to a wider set of outcomes beyond recidivism, with a particular focus on health and wellbeing of young people.

The aim of this study was therefore to evaluate the effectiveness and cost-effectiveness of the Gateway programme issued as a conditional caution, compared to usual process (a court appearance or a different conditional caution), in relation to health and wellbeing of its clients.

## Methods

A summary of the study methods is given here; full details are available in the published protocol paper (8), and the first and latest version of the protocol in the supplementary materials.

### *Study design*

The Gateway study was a pragmatic, multicentre, superiority randomised controlled trial (RCT) that compared two groups of young adults who had committed a low-level offence. Participants were randomised to either the Gateway conditional caution (intervention) or disposal as usual to a court summons or a different conditional caution (usual process). An economic evaluation was planned and a qualitative evaluation of the impact of the intervention on participants and other stakeholders is reported elsewhere.

Participants were recruited from four sites (Southampton, Portsmouth, Isle of Wight and Basingstoke), covering the whole of Hampshire and Isle of Wight. Follow-up was carried out at 4-weeks, 16-weeks and 1-year post-randomisation.

### *Participants*

Participants were eligible if they were aged 18-24 years, resided in the Hampshire and Isle of Wight area, were anticipated to give a guilty plea and there was sufficient evidence to provide a realistic prospect of conviction, and it was in the public interest to prosecute or offer a conditional caution to the suspect. Exclusion criteria included serious and indictable only offences, and those involving violence, hate, serious injury, drink-driving, breach of offence orders and any serious previous conviction.

### *Recruitment*

By law the police must know the destination for an offender at the time of disposal, that is, when the outcome of the investigation is administered. As the intervention was one of the disposal



1  
2  
3 options, randomisation had to take place at the time of disposal. HC investigators were trained to  
4 identify, recruit and randomise participants, an approach that had previously been used (9).  
5  
6

7  
8 It was not felt appropriate for police investigators to obtain full consent because of the potential risk  
9 of coercion, nor was it practical, given the timelines. We therefore developed a two-stage consent  
10 procedure. During processing in custody, investigators identified potentially eligible participants and  
11 discussed with them the Gateway caution. For legal reasons, the Gateway caution was initially  
12 offered as a disposal option independently of the study. If interest was shown, the young person was  
13 then informed about the study. A Gateway Caution information leaflet (produced by HC  
14 independently of the study) and a study leaflet with a link to an explanatory video were shared.  
15 Potential participants were made aware that further details about the study would be provided by a  
16 researcher and that they could withdraw from the study at any time without giving a reason. If the  
17 young person was interested in the opportunity to receive Gateway and take part in the study, the  
18 investigator obtained stage 1 consent. This allowed HC to share their contact details with the  
19 University of Southampton (UoS) researchers and gave York Trials Unit (YTU) researchers access to  
20 their police record for demographics such as age, gender and ethnicity and offending history, trigger  
21 offence and any subsequent reoffending.  
22  
23

24 Some participants were out of custody when it was decided the arrest criteria had been met and/or  
25 Gateway was suitable. For these participants, verbal consent was obtained over the telephone and  
26 randomisation undertaken at that time. It was therefore possible that the subsequent in person  
27 disposal for some of these participants could occur several weeks after randomisation depending on  
28 when the in-person disposal could be arranged.  
29  
30

31 Ahead of the week 4 data collection time point, the researchers attempted to contact participants by  
32 telephone, text, email and/or post to arrange an interview. Once arranged, the Stage 2 participant  
33 information sheet was emailed or posted to the participant. At the interview the researcher went  
34 through the information sheet providing explanations as required. If the patient consented, data  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 collection could occur at the same interview or on a subsequent day. To maximise data collection, if  
4  
5 a participant took part in the week 16 interview having not taken part at week 4, verbal consent was  
6  
7 obtained at that point.  
8  
9

### 10 ***Randomisation and blinding***

11  
12  
13 Police officers and investigators (hereafter referred to as investigators) coming into contact with  
14  
15 potential participants were offered opportunities to undergo related training prior to the start of the  
16  
17 study, as well as once the study was live, which was aimed mainly at new staff and as refresher  
18  
19 training. Potential participants were screened using an online eligibility tool hosted by Alchemer and  
20  
21 developed by HC in discussion with YTU. Eligible young people were consented by investigators using  
22  
23 a guidance script developed jointly by HC and the research team. Consenting participants were  
24  
25 randomised using a 1:1 allocation ratio with simple randomisation. Researchers involved in  
26  
27 consenting and collecting data from participants were blind to allocation. It was not possible to blind  
28  
29 participants due to the nature of the intervention.  
30  
31  
32  
33

### 34 ***Intervention and usual care***

35  
36  
37 The Gateway conditional caution was a police-led intervention delivered using a multi-agency  
38  
39 approach.  
40  
41

42 The Gateway intervention consisted of three compulsory parts.  
43  
44

- 45 1. Within 3-5 working days of their disposal, the participant met with a Gateway navigator for a  
46  
47 needs assessment. The navigator then assisted the young adult into the appropriate  
48  
49 services, including Gateway partner agencies (e.g. housing, alcohol, drug and mental health  
50  
51 services). The navigators also undertook midway and final assessments and provided  
52  
53 mentoring throughout the programme. The Gateway navigators were trained practitioners,  
54  
55 provided by a third sector organisation, No Limits, and by Southampton City Council.  
56  
57  
58  
59  
60

- 2.
3. Attendance at two LINX workshops run by The Hampton Trust aimed to assist young adults in the development of cognitive and affective empathy and prevent reoffending. These were delivered between weeks 2-3 and 5-6 post randomisation.
3. Undertaking not to reoffend during the 16 weeks of the conditional caution.

Additional conditions could also be added at the discretion of the supervising officer approving the disposal destination. If a participant reoffended during the period of their caution, the HC Gateway Team could use their discretion when deciding whether a breach had occurred. If a participant was considered to have breached the terms of the caution, they were withdrawn from the Gateway intervention, and the original investigator considered whether to prosecute the participant for the original offence. Participants who breached their Gateway Conditional Caution continued to be approached for data collection.

Participation in Restorative Justice could be requested by the victim, but this was not part of the standard Gateway caution.

Usual process consisted of either a different conditional caution or the participant being charged to appear in court. Examples of conditions attached to the usual process caution include apology letters, victim awareness courses, drug or alcohol diversion courses, fines and compensation.

### **Changes to the intervention and usual process as a result of the COVID-19 pandemic**

In response to government restrictions, on 22 March 2020 HC halted all conditional caution activities that involved face-to-face interaction. The in-person nature of the Gateway intervention meant delivery modes had to change. The Navigators modified their practice to undertake needs assessments and meetings with clients by telephone as standard. The content and purpose of the initial needs assessment and subsequent contact remained the same. The Hampton Trust modified the workshops to be delivered one-to-one over the telephone. The principles and key elements of

1  
2  
3 the workshops were maintained but reduced in length from 10 hours to two hours. Face-to-face  
4  
5 working returned in May 2021, where appropriate and risk assessed.  
6  
7

8 In terms of usual care, simple cautions and conditional cautions with conditions relating to fines,  
9  
10 compensation and apology letters continued to be issued; court proceedings were halted. However,  
11  
12 as the intervention was unavailable, recruitment was halted on 23<sup>rd</sup> March 2020. In August 2020, HC  
13  
14 restarted all conditional cautions, including Gateway.  
15  
16

### 17 18 **Outcomes**

19  
20 The primary outcome was the Warwick-Edinburgh Wellbeing Scale (WEMWBS), which measures  
21  
22 mental health and wellbeing. The WEMWBS consists of 14 items, each with a 5-point scale. The total  
23  
24 score ranges from 14-70, with a higher score indicating a higher level of health and wellbeing.  
25  
26

27  
28 The patient-reported secondary outcomes were the Short Form-12 (SF-12) mental and physical  
29  
30 components, Alcohol Use Disorders Identification Test (AUDIT) and Adolescent Drug Involvement  
31  
32 Scale (ADIS) scores. The ADIS also has an additional section on the use of different types of drugs  
33  
34 that enables a score titled the Index of Multiple Drug Use to be scored. This was not a study  
35  
36 outcome but is reported in the results. Secondary outcomes measuring recidivism one-year post-  
37  
38 randomisation were the total number of police records management system (RMS) incidents, the  
39  
40 total number of RMS incidents resulting in being charged or cautioned, the total number of police  
41  
42 national computer (PNC) convictions, whether the participant was charged with a summary or  
43  
44 either-way offence and whether the participant was charged with an indictable only offence. In the  
45  
46 statistical analysis plan it was originally stated the first two recidivism outcomes would be the total  
47  
48 number of RMS incidents plus the total number of PNC convictions up to one-year post-  
49  
50 randomisation and the total number of RMS incidents resulting in being charged or cautioned plus  
51  
52 the total number of PNC convictions. However, on receipt of the RMS and PNC data we found that a  
53  
54 single offence could be classed as both an incident in the RMS data and a conviction in the PNC data,  
55  
56  
57  
58  
59  
60

1  
2  
3 and hence would lead to double counting when deriving these two recidivism outcomes. It was  
4  
5 therefore decided to separate out the number of PNC convictions and report it as its own outcome.  
6  
7

### 8 ***Patient and public involvement***

9

10  
11 PPI was embedded early on with the help of partners The Hampton Trust (HT). Meetings with young  
12  
13 adults on an HT programme explored various aspects of the study, including importance,  
14  
15 acceptability and feasibility. The groups fed back in detail around the logistics of the study: the  
16  
17 process around consent and randomisation; ways to manage challenges following up the control  
18  
19 arm; and opinion on assessment forms.  
20  
21

22  
23 Once the study was underway, the PPI lead worked with partners to involve young adult  
24  
25 representatives who had been through the Gateway programme and those who had been through  
26  
27 the 'usual process'. Consultation and input from these service users provided a clear understanding  
28  
29 of the challenges and benefits that participants with and without prior experience of the criminal  
30  
31 justice system might face. These PPI representatives worked closely with the PPI lead to develop  
32  
33 consent forms, PISs, and initial information leaflets, plan recruitment strategies and consider the  
34  
35 most effective ways of arranging interviews and qualitative work.  
36  
37

38  
39 There were two public representatives on the Study Steering Committee/Data Monitoring and Ethics  
40  
41 Committee (SSC/DMEC). An ex-offender, working for Hampshire Youth Offenders Team (HYOT) as a  
42  
43 peer mentor and support worker; and a victim advocate, working for a charity for victims of crime.  
44  
45 They represented the voice of the service users and victims at Steering Group meetings, helping the  
46  
47 group reflect on the realities of delivering the programme from the user perspective, reminding the  
48  
49 group of some of the vulnerabilities and needs of this population, and ensuring the views of victims  
50  
51 were considered.  
52  
53

54  
55 These two representatives also worked closely with the study PPI lead, providing strategic input,  
56  
57 advice and guidance throughout, with a particular focus on the logistics of getting the project  
58  
59  
60

1  
2  
3 underway, reviewing and adapting the protocol. The idea of a recruitment video was conceived by  
4  
5 the ex-offender public representative, and the content was co-created with them.  
6  
7

8 Utilising links established through a local outreach programme, community leaders and members of  
9  
10 the public were consulted. We worked closely with these individuals to ensure we understood the  
11  
12 concerns and attitudes of the wider community. Additionally, they were able to provide input to  
13  
14 public facing documentation and materials.  
15  
16

### 17 ***Statistical analysis***

18  
19  
20 It has been suggested that a change of three or more points on the WEMWBS is likely to be  
21  
22 important to individuals, although different statistical approaches provide different estimates  
23  
24 ranging from three to eight points (WEMWBS user guide(10)). Estimates of the standard deviation  
25  
26 also vary between 6 and 10.8(11), with a pooled estimate of 10 across all studies. Assuming 90%  
27  
28 power, 5% statistical significance, a minimal clinically important difference of 5 points on the  
29  
30 WEMWBS and a standard deviation of 10, 266 participants were required. Preliminary figures from  
31  
32 The Hampton Trust's Raising Awareness of Domestic Abuse in Relationships (RADAR) intervention  
33  
34 suggested a drop-out rate of approximately 15%. Assuming a conservative 20% attrition rate, we  
35  
36 aimed to recruit and randomise 334 participants.  
37  
38  
39

40  
41 Analyses were conducted in Stata® version 17 (StataCorp LP; College Station, TX, USA) and followed  
42  
43 a pre-specified statistical analysis plan (SAP) approved by the Study Steering and Data Monitoring  
44  
45 and Ethics Committee prior to the completion of data collection.  
46  
47  
48

49 Version 1.0 of the SAP outlined the planned analyses to assess the effectiveness of the Gateway  
50  
51 intervention, however poor retention and data collection rates made this unfeasible. Version 1.1 of  
52  
53 the SAP removed all reference to formal hypothesis testing and outlined purely descriptive analyses.  
54  
55

56 Continuous measures were summarised using counts, mean, standard deviation, median,  
57  
58 interquartile range (IQR), minimum and maximum. Categorical measures were summarised using  
59  
60

1  
2  
3 counts and percentages. All participants were analysed according to their randomised group, unless  
4  
5 otherwise stated. The flow of participants from eligibility and randomisation to follow-up and  
6  
7 analysis of the trial was presented in a Consolidated Standards of Reporting Trials (CONSORT) flow  
8  
9 diagram.<sup>(12)</sup> Reasons for ineligibility and non-consent were given. The number of withdrawals and  
10  
11 reasons for withdrawal at each time point were summarised descriptively by randomised treatment  
12  
13 group. Participant demographics were summarised descriptively by randomised treatment group,  
14  
15 both for all participants randomised and participants who provided the primary outcome data for at  
16  
17 least one timepoint. No formal statistical comparisons were undertaken between groups.  
18  
19

20  
21 For those who received Gateway, the number of LINX workshops attended, delivery of LINX  
22  
23 workshops, contacts attempted by the navigator, successful contacts made by the navigator and  
24  
25 total duration of successful contacts were summarised descriptively. For participants who were  
26  
27 cautioned, the conditions attached to each caution were summarised descriptively by whether the  
28  
29 participant received the Gateway conditional caution or a different caution.  
30  
31

32  
33 The primary, secondary and exploratory outcomes were summarised descriptively at each timepoint  
34  
35 by randomised group.  
36  
37

38  
39 Intervention compliance was defined as both minimal compliance and full compliance. Minimal  
40  
41 compliance was met when the participants engaged with their navigator at the initial, midway and  
42  
43 final assessments, attended the two LINX workshops and had not been breached for reoffending  
44  
45 during the duration of the conditional caution. Full compliance was met when the conditions for  
46  
47 minimal compliance were met, and in addition the participant engaged with external agencies  
48  
49 organised by the navigator.  
50  
51

52  
53 The number and proportion of participants informed of their disposal decision after their 4-week  
54  
55 follow-up was due, was presented by randomised treatment group. The number of days between  
56  
57 randomisation and date of disposal were summarised descriptively, alongside whether the  
58  
59 participant attended their 4-week follow-up. The number and proportion of participants in the  
60

1  
2  
3 intervention group who violated the condition to reoffend was presented. For these participants, the  
4 number for whom discretion was considered before taking the decision to breach was reported.  
5  
6  
7

## 8 **Results**

9

10  
11 Due to issues with retention of participants and data collection rates, recruitment ended on 13<sup>th</sup>  
12 December 2021, and data was collected for participants due up until 31<sup>st</sup> March 2022.  
13  
14

15  
16 Between the 1<sup>st</sup> of October 2019 and 13<sup>th</sup> December 2021 345 potentially eligible young people were  
17 screened, of which 298 (86.4%) were eligible. Of the 298 eligible, 106 (35.6%) did not consent to the  
18 study. Of these, 77 (72.6%) refused the study but accepted the Gateway caution; 5 (4.7%) refused  
19 the Gateway caution; 2 (1.9%) ran out of prosecution time; and 2 (1.9%) were missed by the  
20 recruiting investigator (reason unknown). There were 20 (18.9%) for whom the reason for non-  
21 consent is unknown. In total, 192 (64.4%) participants were recruited and randomised. One  
22 participant was randomised in error, which led the custody sergeant to non-randomly assign the  
23 participant. This participant is excluded from all further analyses, meaning 191 participants were  
24 randomised and included in the analyses (Gateway 109; usual process 82; Figure 1).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **INSERT FIGURE ONE HERE**

38  
39 The mean age of participants was 20.8 years (range 18.1-24.8) and 144 (78.7%) were male (Table 1).  
40  
41 The median total number of RMS incidents involved in 1-year pre-randomisation was 6 (3, 13), with  
42 57 (31.5%) participants involved in an RMS incident that led to a caution or charge during this  
43 period. Baseline characteristics of the randomised participants were generally balanced between  
44 groups, except for small imbalances in gender and highest level of education. For participants who  
45 provided a valid WEMWBS score, there was an imbalance in the proportion of participants  
46 previously convicted that was larger than the imbalance observed in all randomised participants.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1:** Participant characteristics presented by allocated group, for all randomised participants and all randomised participants who provided a valid WEMWBS score for at least one timepoint.

	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
<b>Age at randomisation</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Mean (SD)	20.8 (2.0)	20.7 (1.9)	20.8 (1.9)	20.7 (2.0)	20.7 (1.7)	20.7 (1.9)
Median (IQR)	20.3 (19.3, 22.5)	20.4 (19.3, 21.6)	20.4 (19.3, 22.0)	20.2 (19.0, 22.3)	20.5 (19.4, 21.4)	20.3 (19.3, 21.6)
Min, Max	18.1, 24.8	18.1, 24.8	18.1, 24.8	18.1, 24.7	18.1, 24.7	18.1, 24.7
<b>Gender, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Male	87 (82.9)	57 (73.1)	144 (78.7)	51 (79.7)	32 (72.7)	83 (76.9)
Female	18 (17.1)	21 (26.9)	39 (21.3)	13 (20.3)	12 (27.3)	25 (23.1)
<b>Marital status, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Single	62 (93.9)	38 (86.4)	100 (90.9)	60 (93.8)	38 (86.4)	98 (90.7)
Living with partner	4 (6.1)	5 (11.4)	9 (8.2))	4 (6.2)	5 (11.4)	9 (8.3)
Married	0 (0)	1 (2.3)	1 (0.9)	0 (0)	1 (2.3)	1 (0.9)
<b>Ethnicity, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>182 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>108 (100)</b>
White North European	96 (91.4)	75 (96.2)	170 (93.4)	58 (90.6)	44 (100)	102 (94.4)
Black	5 (4.8)	2 (2.6)	7 (3.8)	3 (4.7)	0 (0)	3 (2.8)
Asian	2 (1.9)	1 (1.3)	3 (1.6)	1 (1.6)	0 (0)	1 (0.9)
White South European	1 (1.0)	0 (0)	1 (0.5)	1 (1.6)	0 (0)	1 (0.9)
<b>Highest level of education, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
No qualifications	14 (21.2)	3 (6.8)	17 (15.5)	14 (21.9)	3 (6.8)	17 (15.7)
1-4 GCSEs	20 (30.3)	8 (18.2)	28 (25.5)	20 (31.3)	8 (18.2)	28 (25.9)
More than 5 GCSEs	13 (19.7)	11 (25.0)	24 (21.8)	13 (20.3)	11 (25.0)	24 (22.2)
Apprenticeship	2 (3.0)	5 (11.4)	7 (6.4)	2 (3.1)	5 (11.4)	7 (7.5)
2 or more A- levels	17 (25.8)	15 (34.1)	32 (29.1)	15 (23.4)	15 (34.1)	30 (27.8)
Bachelor's degree or higher	0 (0)	2 (4.5)	2 (1.8)	0 (0)	2 (4.5)	2 (1.9)
<b>IMD quintile (1=most deprived, 5=least deprived), n (%)</b>						
<b>Number with data, n (%)</b>	<b>94 (86.2)</b>	<b>72 (87.8)</b>	<b>166 (86.9)</b>	<b>58 (90.6)</b>	<b>42 (95.5)</b>	<b>100 (92.6)</b>
1	21 (22.3)	20 (27.8)	41 (24.7)	14 (24.1)	14 (33.3)	28 (28.0)
2	25 (26.6)	17 (23.6)	42 (25.3)	14 (24.1)	9 (21.4)	23 (23.0)
3	15 (16.0)	14 (19.4)	29 (17.5)	9 (15.5)	8 (19.0)	17 (17.0)
4	16 (17.0)	7 (9.7)	23 (13.9)	9 (15.5)	4 (9.5)	13 (13.0)
5	17 (18.1)	14 (19.4)	31 (18.7)	12 (20.7)	7 (16.7)	19 (19.0)
<b>Entry route, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>77 (93.9)</b>	<b>182 (95.3)</b>	<b>64 (100)</b>	<b>43 (97.8)</b>	<b>107 (99.1)</b>
Caution	93 (88.6)	72 (93.5)	165 (90.7)	57 (89.1)	42 (97.7)	99 (92.5)

	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
Prosecution	12 (11.4)	5 (6.5)	17 (9.3)	7 (10.9)	1 (2.3)	8 (7.5)
<b>Total number of RMS incidents involved in 1-year pre-randomisation (not including RMS incident that led to study entry)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	10.8 (12.5)	12.9 (25.7)	11.7 (19.2)	9.3 (8.7)	9.0 (9.9)	9.2 (9.2)
Median (IQR)	7 (3, 13)	6 (3, 12)	6 (3, 13)	6 (3, 13)	5 (3, 12)	6 (3, 13)
Min, Max	0, 79	1, 200	0, 200	0, 35	1, 38	0, 38
<b>Total number of RMS incidents leading to charge or caution 1-year pre-randomisation (not including charge or caution that led to study entry)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.6 (1.0)	0.5 (1.3)	0.5 (1.1)	0.6 (1.0)	0.3 (0.6)	0.5 (0.9)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0.5)	0 (0, 1)
Min, Max	0, 4	0, 10	0, 10	0, 4	0, 2	0, 4
<b>Total number of PNC convictions 1-year pre-randomisation</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.5 (0.8)	0.3 (0.5)	0.4 (0.7)	0.4 (0.7)	0.2 (0.5)	0.3 (0.6)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 2	0, 3	0, 2	0, 2	0, 2
<b>Involved in RMS incident that led to caution or charge 1-year pre-randomisation (not including charge or caution that led to study entry), n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	36 (34.6)	21 (27.3)	57 (31.5)	21 (33.3)	11 (25.0)	32 (29.9)
No	68 (65.4)	56 (72.7)	124 (68.5)	42 (66.7)	33 (75.0)	75 (70.1)
<b>PNC conviction 1-year pre-randomisation, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	31 (29.8)	22 (28.6)	53 (29.3)	16 (25.4)	8 (18.2)	24 (22.4)
No	73 (70.2)	55 (71.4)	128 (70.7)	47 (74.6)	36 (81.8)	83 (77.6)
N = number; Min = minimum; Max = maximum; SD = standard deviation; RMS = record management system; PNC = police national computer						

Of the 109 participants randomly assigned Gateway, 104 (95.4%) received Gateway with four of the remaining five receiving a standard caution. Of the 81 (98.8%) participants who were randomly assigned to and received usual process, 76 (93.8%) entered the study via the caution route i.e. received a different conditional caution. There were 18 (17.1%) who received a Gateway caution

1  
2  
3 with the additional condition of providing compensation, while 5 (4.8%) were required to write a  
4  
5 letter of apology to the victim. Of those who received a simple or conditional caution, the most  
6  
7 common conditions attached were compensation (n=20; 25.0%), attending a drug diversion course  
8  
9 (n=16; 20.0%) and attending a victim awareness course (n=14; 17.5%).

10  
11  
12 Of the 105 participants who received Gateway, data on number of LINX sessions attended was received  
13  
14 for 101 (96.2%), of which 88 (87.1%) attended both sessions, 1 (1.0%) attended one session, 8 (7.9%)  
15  
16 did not attend any sessions, while 4 (4.0%) could not attend due to the COVID-19 pause. Of those  
17  
18 who attended at least one workshop, 45 (56.3%) attended a face-to-face workshop while 35 (43.8%)  
19  
20 had the workshop delivered via the telephone. The median number of successful contacts made by  
21  
22 the navigator to the participant was 19 (IQR 15 to 31). For each participant the total duration of  
23  
24 successful contacts was calculated, the median of which was 626.5 minutes (IQR 380, 978). Further  
25  
26 information on the delivery of Gateway and usual process is presented in Appendix A in the  
27  
28 supplementary materials.  
29  
30  
31  
32

33  
34 At the primary endpoint of one-year post-randomisation, 43 (22.5%) case report forms (CRFs) were  
35  
36 returned (Gateway 27, 24.8%; usual process 16, 19.5%) (Figure 1). At 4-weeks post-randomisation 94  
37  
38 (49.2%) CRFs were returned (Gateway 58, 53.2%; usual process 36, 43.9%) while at 16 weeks post-  
39  
40 randomisation 95 (49.7%) (Gateway 56, 51.4%; usual process 39, 47.6%). The WEMWBS, SF-12,  
41  
42 AUDIT and ADIS data for one participant in the Gateway group was excluded at week 4 due to the  
43  
44 questionnaire being completed too early. At week 16 the data for two participants in the Gateway  
45  
46 group were excluded due to the questionnaires being completed too late.  
47  
48  
49

50  
51 Valid participant-reported outcome data was provided by 96 (50.3%) participants at the 4-week  
52  
53 follow-up, 93 (48.7%) participants at the 16-week follow-up and 43 (22.5%) participants at the 1-year  
54  
55 follow-up (Gateway 56, 51.4%; usual process 39, 47.6%). Descriptive summaries of the primary and  
56  
57 secondary outcomes are provided in Table 2 and Table 3 respectively.  
58  
59  
60

There were 129 (67.5%) participants who had reached the one-year follow-up before their RMS data was extracted by HC on the 23<sup>rd</sup> of June 2022, while 125 (65.4%) reached the one-year follow-up before their PNC data was extracted. Ten participants who withdrew before or after stage 2 consent, declined stage 2 consent or lost mental capacity did not have their RMS and PNC data reported. Of the 32 participants in the Gateway group who had been in the study less than one year, 2 (6.3%) had been charged with a summary or either-way offence, while of the 24 participants in the usual process group, 2 (8.3%) had been charged. For the 56 participants who had been in the study less than one year, the mean time between date of randomisation and date of data extraction was 286.9 days (SD 56.7 days). Table 4 gives descriptive summaries of the recidivism outcomes.

**Table 2:** The WEMWBS score at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	44.1 (9.6)	44.9 (7.2)
Median (IQR)	45 (38, 52)	44 (41, 49)
Min, Max	19, 61	28, 62
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	48.6 (9.9)	46.0 (8.5)
Median (IQR)	49 (42, 55)	47 (40, 53)
Min, Max	27, 67	30, 60
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.4 (9.7)	45.7 (7.0)
Median (IQR)	49 (41, 54)	45.5 (41.5, 50.5)
Min, Max	29, 68	28, 58

**Table 3:** Secondary and exploratory participant-reported outcomes at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>SF-12 Mental Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	42.4 (12.0)	43.5 (9.7)
Median (IQR)	43.6 (35.7, 53.1)	43.8 (36.8, 51.9)
Min, Max	15.1, 58.8	22.1, 58.8
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	47.7 (7.6)	45.0 (9.1)
Median (IQR)	47.7 (41.7, 54.6)	45.8 (38.7, 52.7)
Min, Max	34.3, 58.8	20.7, 58.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	47.5 (7.5)	46.1 (8.6)
Median (IQR)	47.7 (39.5, 54.6)	47.5 (44.4, 51.8)
Min, Max	34.3, 58.8	20.7, 58.1

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>SF-12 Physical Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	54.5 (5.3)	52.8 (6.7)
Median (IQR)	55.5 (53.7, 57.4)	55.2 (51.2, 56.8)
Min, Max	36.8, 63.9	30.8, 59.2
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	52.5 (6.4)	53.4 (5.7)
Median (IQR)	54.5 (51.7, 56.0)	55.2 (52.4, 56.9)
Min, Max	26.1, 59.4	38.0, 60.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	51.9 (7.9)	53.5 (6.3)
Median (IQR)	54.5 (51.7, 56.5)	55.3 (52.5, 58.2)
Min, Max	26.1, 59.4	38.0, 58.9
<b>AUDIT</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	12.9 (9.2)	11.2 (7.5)
Median (IQR)	11 (5, 19)	10.5 (5.5, 16.5)
Min, Max	0, 34	0, 28
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	11.6 (8.1)	11.6 (8.7)
Median (IQR)	9.5 (5, 15)	10 (4, 16)
Min, Max	0, 32	0, 36
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	11.1 (8.5)	13.3 (8.3)
Median (IQR)	8 (5, 20)	12.5 (8, 17)
Min, Max	0, 30	1, 30
<b>ADIS</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	46.9 (33.6)	45.1 (36.5)
Median (IQR)	38 (25, 59)	37.5 (12, 76.5)
Min, Max	0, 137	0, 111
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	40.9 (36.3)	37.2 (38.2)
Median (IQR)	36.5 (15, 52)	31 (0, 67)
Min, Max	0, 137	0, 111
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.7 (36.1)	50.5 (39.0)
Median (IQR)	40 (23, 68)	38.5 (20.5, 86)
Min, Max	0, 134	0, 111
<b>Accommodation status (exploratory), n (%)</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Homeless	8 (14.0)	3 (8.3)
Not homeless	49 (86.0)	33 (91.7)
<b>Year 1, n (%)</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Homeless	3 (11.1)	0 (0)
Not homeless	24 (88.9)	15 (100)

**Table 4:** Recidivism outcomes presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>RMS incidents involved in up to one-year post-randomisation</b>		
Number with data, n (%)	<b>74 (67.9)</b>	<b>55 (67.1)</b>
Mean (SD)	9.3 (12.2)	12.2 (23.7)
Median (IQR)	5 (1, 14)	5 (1, 11)
Min, Max	0, 61	0, 132
<b>Total number of RMS incidents resulting in being classed as a suspect and charged/cautioned up to one-year post-randomisation</b>		
Number with data, n (%)	<b>74 (67.9)</b>	<b>55 (67.1)</b>
Mean (SD)	0.4 (1.2)	0.8 (2.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 7	0, 20
<b>Total number of PNC convictions up to one-year post-randomisation</b>		
Number with data, n (%)	<b>72 (66.1)</b>	<b>53 (64.6)</b>
Mean (SD)	0.4 (0.8)	0.4 (0.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 5
<b>Charged with a 'summary' or 'either way' offence up to one-year post-randomisation</b>		
Number with data, n (%)	<b>72 (66.1)</b>	<b>53 (63.9)</b>
Charged	19 (26.4)	16 (30.2)
Not charged	53 (73.6)	37 (69.8)
<b>Charged with an 'indictable only' offence up to one-year post-randomisation</b>		
Number with data, n (%)	<b>72 (66.1)</b>	<b>53 (64.6)</b>
Charged	0 (0)	0 (0)
Not charged	72 (100)	53 (100)

Of the 105 participants randomly allocated to the Gateway conditional caution who did not withdraw before stage 2 or withdraw stage 2 consent, 81 (77.1%) met the definition for minimal compliance. Thirteen participants did not meet minimal compliance due to not attending the two LINX sessions, six did not meet minimal compliance due to breaching the condition to not reoffending during the period of the caution and five were given usual process despite being randomly assigned to the Gateway conditional caution.

No participants were withdrawn from the Gateway conditional caution because they failed to engage with referral agencies identified by the navigator, therefore the number of participants meeting full compliance was 81 (77.1%).

1  
2  
3 Of the 191 randomised participants, 15 (7.9%) were informed of their disposal decision after their 4-  
4 week follow-up was due (Gateway 12, 11.1%; usual process 3, 3.7%; see Appendix B of the  
5 supplementary materials).  
6  
7  
8

9  
10 Of the 105 participants who received the Gateway conditional caution who did not withdraw before  
11 stage 2 or withdraw stage 2 consent, 8 (7.6%) reoffended during the period of the conditional  
12 caution. There were two (25.0%) participants for whom discretion was applied before taking the  
13 decision that they were in breach of the condition not to reoffend. The remaining 6 (75.0%) were  
14 referred back to the original investigator. Due to the risk of data disclosure further information is not  
15 provided here.  
16  
17  
18  
19  
20  
21  
22  
23

24 Information on the Index of Multiple Drug Use, adverse childhood experiences and the health  
25 economic data are presented in appendices C, D and E respectively.  
26  
27  
28  
29

### 30 **Discussion**

31  
32 The Gateway study is the first RCT in the UK police setting to have a health-related primary outcome  
33 requiring individual data collection rather than prioritising criminal justice data on recidivism. Using  
34 a novel two-stage consent process, we demonstrated that it is possible to recruit and randomise  
35 young people who have committed a minor offence to an RCT in the police setting. This was only  
36 possible because of the close collaboration between the research team and Hampshire  
37 Constabulary.  
38  
39  
40  
41  
42  
43  
44  
45

46 A key limitation of the study is that due to high attrition rates, the study was ended early and an  
47 assessment of the effectiveness of the Gateway intervention compared to usual process could not  
48 be completed. Similar issues with the follow-up and the collection of health data have been found in  
49 other community-based studies in disadvantaged populations, especially those with young people.  
50  
51 (13, 14) We implemented numerous strategies to overcome our issues with retention including a  
52 telephone call reminder about the study from the HC Gateway Project Officer before stage 2 consent  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 was due. Our public involvement work with vulnerable young people resulted in valuable  
4 suggestions, which we implemented, including changing the wording on participant facing  
5 information and creating a video explaining the study. We also increased the value of the shopping  
6 gift cards on offer for return of outcome data. In addition, we put into place strategies to improve  
7 recruitment, including expansion of the study catchment area and following up the non-screening of  
8 a potentially eligible participant with the recruiting police staff member to ascertain the factors that  
9 led to this. However, we were unable to solve the barrier presented by out-of-date or invalid contact  
10 details, as well as the lack of response by the participants to contact attempts by the researchers.  
11

12 The groups were generally well balanced in terms of characteristics and percentage providing data,  
13 and allocation did not appear to make any difference to level of engagement. Participants who took  
14 part in data collection interviews completed all parts of the WEMWBS, SF-12, AUDIT and ADIS  
15 instruments at all time points. This suggests that the questions were not overly burdensome or  
16 intrusive and that telephone interviews were acceptable to those willing to share a valid telephone  
17 number.  
18

19 The challenges in recruiting and retaining participants that we faced, and the strategies we put in  
20 place to overcome them will help researchers planning and carrying out future studies with this  
21 population. We have also provided a benchmark for attrition in this population and setting, which  
22 indicates that further work is needed to identify ways to facilitate engagement between researchers  
23 and this vulnerable population.  
24

25 A regression discontinuity design (RDD) may be a pragmatic solution to the recruitment issues  
26 encountered by the Gateway trial,<sup>(15)</sup> that has been used before in the criminal justice setting.<sup>(16,</sup>  
27 17) The RDD is a quasi-experimental design that allocates participants to intervention or control  
28 according to their score on a continuous baseline variable, with the outcome being a continuous  
29 measure. If there is no effect of the intervention, then the regression plots of the allocation variable  
30 against the outcome of interest will be smooth with no interruption at the point of allocation on the  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



pre-test variable. However, if the intervention is effective then there will be a change or discontinuity in the regression slope at the point of allocation.

For example, in the criminal justice setting a prospective RDD could use a standardised offender risk score to assign treatment, with participants scoring above a certain threshold being allocated to the intervention, which is probably more logical and acceptable to staff and offenders than the use of randomisation. A prospective design would allow for outcomes that may not be routinely collected, but are relevant to health care professionals and the police, to be collected as part of the study. In theory, the RDD would mitigate against selection bias by assuming that measurement error around the threshold point produces equivalent groups.

## Conclusion

We have demonstrated that it is possible to recruit and randomise this study population in a police setting, but recruitment and retention estimates should be conservative. However, more work is needed to identify strategies to improve retention rates when carrying out research with this underserved population.

## List of abbreviations

ADIS	Adolescent Drug Involvement Scale
AUDIT	Alcohol Use Disorders Identification Test
CRF	Case Report Form
HC	Hampshire Constabulary
IQR	Interquartile range
PNC	Police National Computer
RCT	Randomised controlled trial
RMS	Record Management System
SAP	Statistical Analysis Plan
SD	Standard deviation
WEMWBS	Warwick-Edinburgh Mental Wellbeing Scale
YTU	York Trials Unit

### ***Ethics approval and consent to participate***

The study protocol, all associated study documents and amendments were approved by the University of Southampton Ethics and Research Information Governance Board (ERGO ID: 31911).

The outline proposal was submitted to the Hampshire Constabulary Ethics Committee, who agreed to support the study. The following external ethics boards confirmed their approval was not required: HRA Research Ethics Service, Social Care REC approval, Her Majesty Prison Probation Services.

### ***Availability of data and materials***

Data will be made available on reasonable request to the study statistician ([alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)), who will consult with the chief investigator and trial management group before a final decision is made.

### ***Competing interests***

Catherine Hewitt was Deputy Chair of the NIHR HTA commissioning board, NIHR CTU Standing Advisory Committee, HTA Post-Funding Committee teleconference and the HTA Funding Committee Policy Group (formerly CSG). James Raftery is a member of the NIHR Editorial Board for HTA and EME. Julie Parkes is Director of Training, UK Faculty of Public Health. There are no other declared competing interests.

### ***Funding***

The Gateway trial was funded by the National Institute of Health Research (NIHR) Public Health Research Programme (award ID: 16/122/20).

### ***Authors' contributions***

1  
2  
3 **Alex Mitchell**, (<https://orcid.org/0000-0001-9311-2092>) (Statistician, Health Sciences), contributed  
4  
5 to the overall study design, wrote the statistical analysis plan, conducted the statistical analysis,  
6  
7 contributed to writing and editing the manuscript.  
8  
9

10 **Alison Booth**, (<https://orcid.org/0000-0001-7138-6295>) (Senior Research Fellow, Health Sciences)  
11  
12 was a co-investigator, contributed to conceptualisation and design, funding acquisition, protocol  
13  
14 development, and was trial manager for the conduct and delivery of the trial, site setup and data  
15  
16 management, manuscript writing and editing.  
17  
18

19  
20 **Sara Morgan**, (<https://orcid.org/0000-0001-8346-6655>) (Lecturer, Public Health) was a co-  
21  
22 investigator, contributed to conceptualisation and design, funding acquisition, protocol  
23  
24 development, conduct and delivery of the trial and qualitative evaluation, data acquisition,  
25  
26 qualitative analysis and manuscript commenting.  
27  
28

29  
30 **Inna Walker**, (<https://orcid.org/0000-0002-8460-8130>) (Clinical Research Fellow, quantitative and  
31  
32 qualitative researcher) contributed to protocol development and study design, conduct and delivery  
33  
34 of the trial and qualitative evaluation, data acquisition, qualitative analysis, manuscript commenting.  
35  
36

37 **Megan Barlow-Pay**, (<https://orcid.org/0000-0003-1473-2096>) (Patient and Public Involvement and  
38  
39 Engagement (PPIE) and researcher) was the PPI lead for the study, undertook PPI work, contributed  
40  
41 to study design and conduct, quantitative data collection qualitative data collection and analysis, and  
42  
43 commenting on the manuscript.  
44  
45

46  
47 **Caroline Chapman**, (<https://orcid.org/0000-0002-6498-5932>) (Sergeant, Gateway Project Support  
48  
49 Officer for Hampshire Constabulary) contributed to protocol development, trial conduct, setting up  
50  
51 of sites, data acquisition and checking, commented on the manuscript.  
52  
53

54 **Ann Cochrane**, (<https://orcid.org/0000-0002-1502-6719>) (Trial Coordinator, Health Sciences),  
55  
56 contributed to protocol development, trial conduct, setting up of sites, data acquisition and  
57  
58 processing and commented on the manuscript.  
59  
60

1  
2  
3 **Emma Filby**, (<https://orcid.org/0000-0002-1090-1123>) (Data administrator, Health Sciences)  
4  
5 contributed to the study conduct, project administration, data management, and commented on the  
6  
7 manuscript.  
8  
9

10 **Jenny Fleming**, (<https://orcid.org/0000-0002-7913-3345>) (Professor in Criminology, qualitative  
11  
12 methodologist) was a co-investigator contributing to conceptualisation and design, funding  
13  
14 acquisition, protocol development, trial conduct, and commenting on the manuscript.  
15  
16

17  
18 **Catherine Hewitt**, (<https://orcid.org/0000-0002-0415-3536>) (Professor in Statistics, Health Sciences)  
19  
20 was a co-investigator, she contributed to conceptualisation and design, funding acquisition, protocol  
21  
22 development, provided oversight of trial conduct and the statistical analysis, and commented on the  
23  
24 manuscript.  
25  
26

27  
28 **James Raftery**, (<https://orcid.org/0000-0003-1094-8578>) (Professor in Health Economics), as a  
29  
30 coinvestigator, contributed to conceptualisation and design, funding acquisition, protocol  
31  
32 development, trial conduct, and commented on the manuscript.  
33  
34

35 **David Torgerson**, (<https://orcid.org/0000-0002-1667-4275>) (Professor, Director of York Trials Unit)  
36  
37 as a co-investigator, contributed to conceptualisation and design, protocol development, funding  
38  
39 acquisition, trial conduct, and commented on the manuscript.  
40  
41

42 **Lana Weir**, (<https://orcid.org/0000-0003-4730-7969>) (Trial Coordinator, qualitative researcher),  
43  
44 contributed to project administration, data acquisition, qualitative analysis, manuscript commenting.  
45  
46

47 **Julie Parkes**, (<https://orcid.org/0000-0002-6490-395X>) (Professor in Public Health) was the Chief  
48  
49 Investigator, and contributed to the conceptualisation and design, funding acquisition, protocol  
50  
51 development, trial conduct, manuscript commenting.  
52  
53

#### 54 **Acknowledgements**

55  
56  
57 We would like to acknowledge and thank all those who contributed to the study.  
58  
59

60 All the young people who took part in the trial and associated interviews.

1  
2  
3 Gateway Navigators provided by No Limits and Southampton City Council who delivered the  
4  
5 intervention; Debbie Willis, Children and Young People's Services Manager and colleagues at The  
6  
7 Hampton Trust, responsible for LINX; those organisations taking referrals from the Navigators: The  
8  
9 Prince's Trust, Two Saints (Housing) and the Community Mental Health Teams across Hampshire and  
10  
11 Isle of Wight, as well as others. Members of the Trial Management Group (TMG) who contributed at  
12  
13 various stages of the study: Inspector Benjamin Taylor (Hampshire Constabulary), Rosanna Orlando  
14  
15 (Health Economist), Anthony Quinn (Qualitative Researcher), Inspector Stuart Baker (Hampshire  
16  
17 Constabulary).

18  
19  
20  
21 Those who supported the study and funded the intervention: Office of Police and Crime  
22  
23 Commissioner (PCC) supporting the PCC for Hampshire and Isle of Wight, and senior management at  
24  
25 Hampshire Constabulary

26  
27  
28 All the police investigators who underwent training and recruited participants into the trial.

29  
30  
31  
32 Members of the Public Participation Panel (PPP), and all the members of the public who contributed  
33  
34 during the development and delivery of the study.

35  
36  
37 The University of Southampton for being the study sponsor and to members of the Study Steering  
38  
39 and Data Monitoring and Ethics Committee for their advice and support.

## 40 41 42 **References**

- 43  
44  
45 1. Alcorn T. Rethinking mental health care for young offenders. *The Lancet*.  
46 2014;383(9925):1283-4.
- 47  
48 2. Underwood LA, Washington A. Mental Illness and Juvenile Offenders. *International Journal of*  
49 *Environmental Research and Public Health*. 2016;13(2):228.
- 50  
51 3. Britton S. Improving Responses To Young Adults. In *Transition to Adulthood Alliance*. UK;  
52 2014.
- 53  
54 4. Petrosino A, Turpin-Petrosino C, Guckenberg S. Formal system processing of juveniles:  
55 Effects on delinquency. *Campbell Systematic Review* 2010(DOI: 10.4073/csr.2010.1).
- 56  
57 5. Weir K, Routledge G, Kili S. Checkpoint: An innovative programme to navigate people away  
58 from the cycle of reoffending: Implementation phase evaluation. *Policing: A Journal of Policy and*  
59 *Practice*. 2021;15(1):508-27.
- 60  
61 6. Neyroud P. Out of court disposals managed by the police: a review of the evidence.  
Commissioned by the National Police Chief's Council of England and Wales University of Cambridge.  
2018.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
7. Wilson DB, Brennan I, Olaghery A. Police-initiated diversion for youth to prevent future delinquent behavior: A systematic review. *Campbell Systematic Reviews*. 2018;14(1):1-88.
8. Cochrane A, Booth A, Walker I, Morgan S, Mitchell A, Barlow-Pay M, et al. Examining the effectiveness of Gateway—an out-of-court community-based intervention to reduce recidivism and improve the health and well-being of young adults committing low-level offences: study protocol for a randomised controlled trial. *Trials*. 2021;22(1):939.
9. Strang H, Sherman L, Ariel B, Chilton S, Braddock R, Rowlinson T, et al. Reducing the Harm of Intimate Partner Violence: Randomized Controlled Trial of the Hampshire Constabulary CARA Experiment. *Camb J Evid Based Polic*. 2017.
10. Stewart-Brown S, K. J. *Warwick-Edinburgh Mental Well-being Scale (WEMWBS): User Guide*. University of Warwick; 2008.
11. Maheswaran H, Weich S, Powell J, Stewart-Brown S. Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): Group and individual level analysis. *Health and Quality of Life Outcomes*. 2012;10(1):156.
12. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.
13. Lankenau SE, Sanders B, Hathazi D, Bloom JJ. Recruiting and retaining mobile young injection drug users in a longitudinal study. *Subst Use Misuse*. 2010;45(5):684-99.
14. Patel MX, Doku V, Tennakoon L. Challenges in recruitment of research participants. *Advances in Psychiatric Treatment*. 2003;9(3):229-38.
15. Reichardt CS. *Experimental and Quasi-Experimental Designs for Generalized Causal Inference*. JSTOR; 2002.
16. Mitchell O. *A Policy Evaluation of Home Detention Sentencing: Evidence from New Zealand*: Auckland University of Technology; 2019.
17. Rhodes W, Jalbert SK. Regression discontinuity design in criminal justice evaluation: An introduction and illustration. *Evaluation Review*. 2013;37(3-4):239-73.




Figure 1: CONSORT diagram demonstrating the progression of participants through the trial.

481x695mm (38 x 38 DPI)

## Appendix A: Delivery of Gateway and usual process

**Table 1:** Conditions attached to cautions, presented by whether the participant received a Gateway conditional caution or a caution forming part of usual process (either a simple caution or a different conditional caution).

	<b>Gateway conditional caution (n=105)</b>	<b>Usual process (n=80)</b>
<b>Conditions attached (multiple conditions possible), n (%)</b>		
Standard Gateway conditions (no additional conditions added)	85 (81.0)	NA
None (simple caution)	NA	5 (6.3)
Compensation	18 (17.1)	20 (25.0)
Letter of apology	5 (4.8)	10 (12.5)
Victim awareness course	0 (0)	14 (17.5)
Alcohol diversion course	0 (0)	11 (13.8)
Drugs diversion course	0 (0)	16 (20.0)
Not to enter specific premises	0 (0)	1 (1.3)
Fine	0 (0)	5 (6.3)
Women and Desistance Empowerment programme	0 (0)	9 (11.3)
Restorative justice	0 (0)	0 (0)

**Table 2:** Information on delivery of the Gateway intervention.

	<b>Received Gateway conditional caution (n=105)</b>
<b>LINX workshops attended (supplemented with change of status data)</b>	
<b>Number with data, n (%)</b>	<b>101 (96.2)</b>
0 (Did not attend LINX sessions due to COVID-19 pause)	4 (4.0)
0 (participant chose to not attend LINX sessions)	8 (7.9)
1 (participant chose not to attend LINX session)	1 (1.0)
2	88 (87.1)
<b>Delivery of LINX workshops</b>	
<b>Number with data, n (% of those who attended at least one workshop)</b>	<b>80 (89.9%)</b>



Face-to-face	45 (56.3)
Telephone	35 (43.8)
<b>Contacts attempted by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	52.8 (25.0)
Median (IQR)	42 (39, 63)
Min, Max	22, 168
<b>Successful contacts made by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	26.0 (20.7)
Median (IQR)	19 (15, 31)
Min, Max	0, 108
<b>Total duration of successful contacts, minutes</b>	
<b>Number with data, n (%)</b>	<b>70 (66.7)</b>
Mean (SD)	761.5 (594.6)
Median (IQR)	626.5 (380, 978)
Min, Max	36, 2785

## Appendix B: Participants informed of their disposal decision after their 4-week follow-up was due

**Table 3:** Information on time between randomisation and disposal decision and whether the 4-week follow-up was attended, for those informed of their disposal decision after the 4-week follow-up was due.

	<b>Gateway conditional caution (n=12)</b>	<b>Usual process (n=3)</b>	<b>Total (n=15)</b>
<b>Time between randomisation and disposal, days</b>			
<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>
Mean (SD)	49.6 (18.1)	NA	NA
Median (IQR)	42 (34.5, 67.5)	NA	NA
Min, Max	29, 77	NA	NA
<b>Attended 4-week follow-up, n (%)</b>			

<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>
Yes	8 (66.7)	NA	NA
No	4 (33.3)	NA	NA

## Appendix C: Index of Multiple Drug Use

**Table 4:** Index of Multiple Drug Use presented at 4-weeks, 16-weeks and 1-year post randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	23.3 (6.4)	21.3 (5.0)
Median (IQR)	22 (18, 27)	21.5 (16.5, 25)
Min, Max	15, 42	15, 31
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	23.3 (7.5)	22.3 (5.9)
Median (IQR)	21 (17, 27)	22 (16, 25)
Min, Max	15, 47	15, 38
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	25.2 (7.7)	25.8 (6.3)
Median (IQR)	23 (18, 31)	25.5 (21, 28.5)
Min, Max	16, 41	16, 38

## Appendix D: Adverse childhood experiences

**Table 5:** Adverse childhood experiences reported at 16 weeks post-randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Number of adverse childhood experiences</b>		
<b>Number with data (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	3.0 (2.6)	3.6 (3.0)
Median (IQR)	2 (1, 5)	4 (1, 5)
Min, Max	0, 10	0, 11

## Appendix E: Health economic analysis

**Table 6:** Health economic data at 4-weeks, 16-weeks and 1-year post-randomisation, presented by group.

	4-weeks post-randomisation		16-weeks post-randomisation		1-year post-randomisation	
	Gateway conditional caution (n=109)	Usual process (n=82)	Gateway conditional caution (n=109)	Usual process (n=82)	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Employed in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Yes	31 (54.4)	16 (44.4)	31 (57.4)	19 (48.7)	16 (59.3)	11 (68.8)
No	26 (45.6)	20 (55.6)	23 (42.6)	20 (51.3)	11 (40.7)	5 (31.3)
<b>Number of times visited GP in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.4 (0.7)	0.5 (1.0)	0.4 (1.0)	0.5 (0.9)	0.5 (1.0)	1.3 (2.6)
Median (IQR)	0 (0, 1)	0 (0, 0.5)	0 (0, 0)	0 (0, 0)	0 (0, 1)	1 (0, 1)
Min, Max	0, 3	0, 4	0, 5	0, 3	0, 4	0, 10
<b>Number of times used drug/alcohol services in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.3 (0.9)	0.3 (1.7)	0.4 (1.2)	0.1 (0.4)	0.2 (0.8)	0.4 (1.1)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 10	0, 5	0, 2	0, 4	0, 4
<b>Number of times visited accident and emergency in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.9)	0.1 (0.2)	0.1 (0.3)	0 (0.2)	0.6 (1.9)	0.2 (0.6)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 6	0, 1	0, 2	0, 1	0, 10	0, 2
<b>Number of times admitted to hospital as inpatient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.1 (0.3)	0 (0)	0.1 (0.3)	0 (0)	0.3 (1.0)	0 (0)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 2	0, 0	0, 2	0, 0	0, 4	0, 0

<b>Number of times used community mental health team in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>35 (2.7)</b>	<b>53 (48.6)</b>	<b>38 (46.3)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.8)	0.2 (0.7)	0.2 (0.6)	1.1 (4.9)	0.4 (1.1)	0.5 (1.2)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 3	0, 3	0, 30	0, 4	0, 4
<b>Number of times used psychiatric services as in-patient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0 (0.2)	0 (0.2)	0 (0)	0.2 (1.0)	0 (0.2)	0.1 (0.3)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 1	0, 1	0, 0	0, 6	0, 1	0, 1
<b>Used the following prescribed medications in previous month, n (%)</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (25.0)</b>	<b>16 (19.3)</b>
Amitriptyline	1 (1.8)	0 (0)	1 (1.9)	0 (0)	2 (7.4)	0 (0)
Aripirazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cerelle	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Citalopram	3 (5.3)	1 (2.8)	1 (1.9)	2 (5.1)	1 (3.7)	0 (0)
Co-codamol	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Codeine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Cyclizine	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Diazepam	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Doxycycline	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Inhaler	0 (0)	4 (11.1)	5 (9.3)	2 (5.1)	1 (3.7)	0 (0)
Escitalopram	1 (1.8)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Fluoxetine	3 (5.3)	1 (2.8)	0 (0)	2 (5.1)	0 (0)	0 (0)
Quetiapine	2 (3.5)	1 (2.8)	0 (0)	0 (0)	0 (0)	1 (6.3)
Lamotrigine	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Lymecycline	0 (0)	2 (5.6)	0 (0)	1 (2.6)	0 (0)	0 (0)
Macrogol 3350	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Melatonin	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Methadone	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Mirtazapine	2 (3.5)	0 (0)	2 (3.7)	0 (0)	1 (3.7)	1 (6.3)
Naproxen	1 (1.8)	0 (0)	2 (3.7)	0 (0)	0 (0)	0 (0)
Omeprazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Ondansetron	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Olanzapine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Phenergan	0 (0)	2 (5.6)	0 (0)	0 (0)	0 (0)	0 (0)
Prednisolone	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Pregabalin	0 (0)	1 (2.8)	1 (1.9)	0 (0)	0 (0)	0 (0)
Prochlorperazine maleate	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Promethazine hydrochloride	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Propranolol hydrochloride	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Quetiapine	2 (3.5)	0 (0)	4 (7.4)	3 (7.7)	2 (7.4)	0 (0)
Ramipril	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Risperidone	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Salbutamol	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6.3)
Sertraline	3 (5.3)	4 (11.1)	7 (13.0)	5 (12.8)	2 (7.4)	2 (12.5)
Prochlorperazine	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Tacrolimus	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Venlafaxine	1 (1.8)	0 (0)	0 (0)	1 (2.6)	1 (3.7)	0 (0)
Vortioxetine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Reason for using prescribed medications in previous month, n (%)</b>						
<b>Number with data (% of those who reported using a medication)</b>						
Acne	0 (0)	3 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)
Anterior cruciate ligament injury	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
ADHD	1 (5.0)	1 (6.7)	1 (4.8)	0 (0)	0 (0)	0 (0)
Anxiety	7 (35.0)	7 (46.7)	4 (19.0)	2 (14.3)	2 (25.0)	2 (28.6)
Asthma	1 (5.0)	4 (26.7)	5 (23.8)	2 (14.3)	1 (12.5)	1 (14.3)
Back pain	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Blood pressure	0 (0)	0 (0)	0 (0)	0 (0)	1 (12.5)	0 (0)
Depression	11 (55.0)	7 (46.7)	8 (38.1)	3 (21.4)	5 (62.5)	2 (28.6)
Ear infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Gastroparesis	1 (5.0)	0 (0)	1 (4.8)	0 (0)	1 (12.5)	0 (0)
Heroin addiction	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Hypertension	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)

Immune system suppression post-kidney transplant	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Inflammation	1 (5.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Insomnia	2 (10.0)	1 (6.7)	0 (0)	1 (7.1)	1 (12.5)	0 (0)
Mood stabilisation	2 (10.0)	1 (6.7)	3 (14.3)	1 (7.1)	1 (12.5)	0 (0)
Nail infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Nausea	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Pain relief	0 (0)	0 (0)	2 (9.5)	0 (0)	1 (12.5)	0 (0)
Panic attacks	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
Psychosis	2 (10.0)	1 (6.7)	1 (4.8)	0 (0)	1 (12.5)	1 (14.3)
PTSD	0 (0)	2 (13.3)	0 (0)	0 (0)	0 (0)	0 (0)



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	4
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	2, 5, 7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	8, 9
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10, 11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	10, 11
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12 and Figure 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	12 and Figure 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	2, 12
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	13, 14
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	10, 16, 17, 18
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	16, 17, 18
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15, 18, 19
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20, 21
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	19, 20, 21
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	19, 20, 21
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	3
Protocol	24	Where the full trial protocol can be accessed, if available	5
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	22

Citation: Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine. 2010;8:18. © 2010 Schulz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).



# BMJ Open

## Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young adults committing low-level offences: a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081179.R1
Article Type:	Original research
Date Submitted by the Author:	13-Mar-2024
Complete List of Authors:	Mitchell, Alex; University of York, Department of Health Sciences Booth, Alison; University of York, UK, Department of Health Sciences Morgan, Sara; University of Southampton Walker, Inna; University of Southampton Chapman, Caroline; Hampshire Constabulary Barlow-Pay, Megan; University of Southampton Cochrane, Ann; University of York, Department of Health Sciences Filby, Emma; University of York, Department of Health Sciences Fleming, Jenny; University of Southampton Highfield Campus, Department of Sociology Hewitt, Catherine; The University of York, Health Sciences Raftery, James; Southampton University, WIHRD, School of Medicine Torgerson, David; The University of York Weir, Lana; University of Southampton Parkes, Julie; University of Southampton, Public Health Sciences and Medical Statistics
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Public health
Keywords:	PUBLIC HEALTH, Adolescents < Adolescent, Randomized Controlled Trial

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young**  
4 **adults committing low-level offences: a randomised controlled trial**  
5  
6  
7

8 **Authors:** Alex Mitchell<sup>1</sup>, Alison Booth<sup>1</sup>, Sara Morgan<sup>2</sup>, Inna Walker<sup>2</sup>, Caroline Chapman<sup>3</sup>, Megan  
9 Barlow-Pay<sup>2</sup>, Ann Cochrane<sup>1</sup>, Emma Filby<sup>1</sup>, Jenny Fleming<sup>4</sup>, Catherine Hewitt<sup>1</sup>, James Raftery<sup>2</sup>, David  
10 J. Torgerson<sup>1</sup>, Lana Weir<sup>2</sup>, Julie Parkes<sup>2</sup>  
11  
12  
13

- 14  
15  
16 1. York Trials Unit, Department of Health Sciences, Faculty of Sciences, University of York, York,  
17 UK  
18  
19 2. School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine,  
20 University of Southampton, Southampton, UK  
21  
22 3. Southampton Central Police Station, Hampshire Constabulary, Southampton, UK  
23  
24 4. Department of Sociology, Social Policy and Criminology, Faculty of Social Sciences, University  
25 of Southampton Highfield Campus, Southampton, UK  
26  
27  
28  
29  
30  
31

32 **Corresponding author:** Alex Mitchell, York Trials Unit, Department of Health Sciences, University of  
33 York, York, UK; [alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Background:** Young adults who commit low-level offences commonly have a range of health and social needs and are significantly over-represented in the criminal justice system. These young adults may need to attend court and potentially receive penalties including imprisonment. Alternative routes exist, which can help address the underlying causes of offending. Some feel more should be done to help young adults entering the criminal justice system. The Gateway programme was a type of out-of-court disposal (OOCd) developed by Hampshire Constabulary, which aimed to address the complex needs of young adults who commit low-level crimes. This study aimed to evaluate the effectiveness and cost-effectiveness of the Gateway programme, issued as a conditional caution, compared to usual process.

**Methods:** The Gateway study was a pragmatic, parallel-group, superiority randomised controlled trial (RCT) that recruited young adults who had committed a low-level offence from four sites covering Hampshire and Isle of Wight. The primary outcome was mental health and wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcomes were quality of life, alcohol and drug use, and recidivism. Outcomes were measured at 4, 16 and 52 weeks post-randomisation.

**Results:** Due to issues with retention of participants and low data collection rates, recruitment ended early, with 191 eligible participants randomised (Gateway 109; usual process 82). The primary outcome was obtained for 93 (48.7%) participants at 4 weeks, 93 (48.7%) at 16 weeks and 43 (22.5%) at 1 year.

**Conclusions:** Gateway is the first trial in a UK police setting to have a health-related primary outcome requiring individual data collection, rather than focusing solely on recidivism. We demonstrated that it is possible to recruit and randomise from the study population, however follow-up rates were low. Further work is needed to identify ways to facilitate engagement between researchers and vulnerable populations to collect data.

1  
2  
3 **Trial registration:** ISRCTN11888938  
4  
5

6 **Keywords:** young adults; criminal justice; recidivism; police; vulnerable populations  
7  
8

9 **Word count:** 4568  
10  
11

### 12 **Strengths and limitations of this study**

13  
14

- 15 • The planned pragmatic trial was robustly and transparently planned and involved  
16 close collaboration between a wide range of stakeholders.
- 17 • We were not able to assess effectiveness of the Gateway intervention due to low  
18 data collection rates.
- 19 • Our work on this trial has provided a robust benchmark for attrition which will help  
20 guide future health related trials in the police setting and with 18-24-year old's  
21 committing low level crimes.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Background**

49

50 Young adults who commit low-level offences commonly have a range of health and social needs,  
51 making them vulnerable to mental health problems. (1-3) These young offenders are more likely to  
52 come into contact with the police both as suspects and victims of crime and are significantly over-  
53 represented in the criminal justice system, accounting for approximately one third of police,  
54 probation and prison caseloads. (4) According to statistics from Hampshire Constabulary (HC) for  
55  
56  
57  
58  
59  
60

1  
2  
3 2018/20, the five main low-level offence categories for adults aged between 18 and 24 where formal  
4 action was taken by the police are possession of drugs, violence, shoplifting, criminal damage and  
5 public order offences. Young adults who have been investigated for a suspected low-level offence,  
6  
7 may need to attend court and, if convicted, face penalties such as prison.  
8  
9

10  
11  
12 More could be done to help young adults entering the criminal justice system, for example via court  
13 diversion programmes. Diversion is a process whereby an accused person is formally moved into a  
14 programme in the community, such as an out-of-court community-based intervention (OCBI),  
15 instead of a court summons. (5) In the UK, a number of police forces are exploring the use of out-of-  
16 court disposals (an alternative to a court summons) amongst 18–24-year-olds involved in less serious  
17 offending. (6-9) The aim is to divert the young adult away from their offending behaviour through a  
18 rehabilitative path. (10)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 The Gateway programme was issued as a novel form of conditional caution, where release from  
30 custody comes with mutually agreed conditions. Gateway was conceived by HC as a culture-  
31 changing initiative that sought to address the complex needs of adults aged 18-24 years who commit  
32 low-level crimes. However, HC recognised the need for evidence on the effectiveness of Gateway  
33 and were keen on an evaluation of its effectiveness in relation to a wider set of outcomes beyond  
34 recidivism, with a particular focus on health and wellbeing of young people.  
35  
36  
37  
38  
39  
40  
41  
42

43 The aim of this study was therefore to evaluate the effectiveness and cost-effectiveness of the  
44 Gateway programme issued as a conditional caution, compared to usual process (a court  
45 appearance or a different conditional caution), in relation to health and wellbeing of its clients.  
46  
47  
48  
49

## 50 **Methods**

51  
52  
53 A summary of the study methods is given here; full details are available in the published protocol  
54 paper (11), and the protocol available at <https://www.fundingawards.nihr.ac.uk/award/16/122/20>.  
55  
56  
57

## 58 **Study design**

1  
2  
3 The Gateway study was a pragmatic, multicentre, superiority randomised controlled trial (RCT) that  
4 compared two groups of young adults who had committed a low-level offence. Participants were  
5 randomised to either the Gateway conditional caution (intervention) or disposal as usual to a court  
6 summons or a different conditional caution (usual process). An economic evaluation was planned. A  
7 qualitative evaluation of the impact of the intervention on participants and other stakeholders will  
8 be reported elsewhere.  
9  
10  
11  
12  
13  
14  
15  
16

17 Participants were recruited from four sites (Southampton, Portsmouth, Isle of Wight and  
18 Basingstoke Police Stations), covering the whole of Hampshire and Isle of Wight. Follow-up was  
19 carried out at 4-weeks, 16-weeks and 1-year post-randomisation.  
20  
21  
22  
23  
24

### 25 **Participants**

26  
27 Participants were eligible if they were aged 18-24 years, resided in the Hampshire and Isle of Wight  
28 area, were anticipated to give a guilty plea and there was sufficient evidence to provide a realistic  
29 prospect of conviction, and it was in the public interest to prosecute or offer a conditional caution to  
30 the suspect. Exclusion criteria included serious and indictable only offences, and those involving  
31 domestic or sexual violence, knives, hate, serious injury, drink-driving, breach of offence orders and  
32 any serious previous conviction. Those needing an interpreter or having a previous Gateway caution  
33 were excluded.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Recruitment**

45  
46 By law the police must know the destination for an offender at the time of disposal, that is, when  
47 the outcome of the investigation is administered. As the intervention was one of the disposal  
48 options, randomisation had to take place at the time of disposal. HC investigators were trained to  
49 identify, recruit and randomise participants, an approach that had previously been used (12).  
50  
51  
52  
53  
54

55  
56 It was not felt appropriate for police investigators to obtain full consent because of the potential risk  
57 of coercion, nor was it practical, given the timelines. We therefore developed a two-stage consent  
58  
59  
60

1  
2  
3 procedure. During processing in custody, investigators identified potentially eligible participants and  
4  
5 discussed with them the Gateway caution. For legal reasons, the Gateway caution was initially  
6  
7 offered as a disposal option independently of the study. If interest was shown, the young person was  
8  
9 then informed about the study. A Gateway Caution information leaflet (produced by HC  
10  
11 independently of the study) and a study leaflet with a link to an explanatory video were shared.  
12  
13  
14 Potential participants were made aware that further details about the study would be provided by a  
15  
16 researcher and that they could withdraw from the study at any time without giving a reason. If the  
17  
18 young person was interested in the opportunity to receive Gateway and take part in the study, the  
19  
20 investigator obtained stage 1 consent. This allowed HC to share their contact details with the  
21  
22 University of Southampton (UoS) researchers and gave York Trials Unit (YTU) researchers access to  
23  
24 their police record for demographics such as age, gender and ethnicity and offending history, trigger  
25  
26 offence and any subsequent reoffending. This process precluded the collection of baseline outcome  
27  
28 data.  
29  
30

31  
32  
33 Some participants were out of custody when it was decided the arrest criteria had been met and/or  
34  
35 Gateway was suitable. For these participants, verbal consent was obtained over the telephone and  
36  
37 randomisation undertaken at that time. It was therefore possible that the subsequent in person  
38  
39 disposal for some of these participants could occur several weeks after randomisation depending on  
40  
41 when the in-person disposal could be arranged. Study procedures continued as per protocol.  
42  
43

44  
45 Ahead of the week 4 data collection time point, the researchers attempted to contact participants by  
46  
47 telephone, text, email and/or post to arrange an interview. Once arranged, the Stage 2 participant  
48  
49 information sheet was emailed or posted to the participant. At the interview the researcher went  
50  
51 through the information sheet providing explanations as required. If the patient consented, data  
52  
53 collection could occur at the same interview or on a subsequent day. To maximise data collection, if  
54  
55 a participant took part in the week 16 interview having not taken part at week 4, verbal consent was  
56  
57 obtained at that point.  
58  
59  
60



### ***Randomisation and blinding***

Police officers and investigators (hereafter referred to as investigators) coming into contact with potential participants were offered opportunities to undergo related training prior to the start of the study, as well as once the study was live, which was aimed mainly at new staff and as refresher training. Potential participants were screened using an online eligibility tool hosted by Alchemer and developed by HC in discussion with YTU. Eligible young people were consented by investigators using a guidance script developed jointly by HC and the research team. Consenting participants were randomised using a 1:1 allocation ratio with simple randomisation. Researchers involved in consenting and collecting data from participants were blind to allocation. It was not possible to blind participants due to the nature of the intervention.

### ***Intervention and usual care***

The Gateway conditional caution was a police-led intervention delivered using a multi-agency approach.

The Gateway intervention consisted of three compulsory parts.

1. Within 3-5 working days of their disposal, the participant met with a Gateway navigator for a needs assessment. The navigator then assisted the young adult into the appropriate services, including Gateway partner agencies (e.g. housing, alcohol, drug and mental health services). The navigators also undertook midway and final assessments and provided mentoring throughout the programme. The Gateway navigators were trained support workers, provided by a third sector organisation, No Limits, and by Southampton City Council.
2. Attendance at two LINX workshops run by The Hampton Trust aimed to assist young adults in the development of cognitive and affective empathy and prevent reoffending. These were delivered between weeks 2-3 and 5-6 post randomisation.

3. Undertaking not to reoffend during the 16 weeks of the conditional caution.

Additional conditions could also be added at the discretion of the supervising officer approving the disposal destination. If a participant reoffended during the period of their caution, the HC Gateway Team could use their discretion when deciding whether a breach had occurred. If a participant was considered to have breached the terms of the caution, they were withdrawn from the Gateway intervention, and the original investigator considered whether to prosecute the participant for the original offence. Participants who breached their Gateway Conditional Caution continued to be approached for data collection.

Participation in Restorative Justice could be requested by the victim, but this was not part of the standard Gateway caution.

Usual process consisted of either a different conditional caution or the participant being charged to appear in court. Examples of conditions attached to the usual process caution include apology letters, victim awareness courses, drug or alcohol diversion courses, fines and compensation.

### **Changes to the intervention and usual process as a result of the COVID-19 pandemic**

In response to government restrictions, on 22 March 2020 HC halted all conditional caution activities that involved face-to-face interaction. The in-person nature of the Gateway intervention meant delivery modes had to change. The Navigators modified their practice to undertake needs assessments and meetings with clients by telephone as standard. The content and purpose of the initial needs assessment and subsequent contact remained the same. The Hampton Trust modified the workshops to be delivered one-to-one over the telephone. The principles and key elements of the workshops were maintained but reduced in length from 10 hours to two hours. Face-to-face working returned in May 2021, where appropriate and risk assessed.

In terms of usual care, simple cautions and conditional cautions with conditions relating to fines, compensation and apology letters continued to be issued; court proceedings were halted. However,

1  
2  
3 as the intervention was unavailable, recruitment was halted on 23<sup>rd</sup> March 2020. In August 2020, HC  
4  
5 restarted all conditional cautions, including Gateway.  
6  
7

## 8 **Outcomes**

9  
10 The primary outcome was the Warwick-Edinburgh Wellbeing Scale (WEMWBS), which measures  
11  
12 mental health and wellbeing. The WEMWBS consists of 14 items, each with a 5-point scale. The total  
13  
14 score ranges from 14-70, with a higher score indicating a higher level of health and wellbeing.  
15  
16

17  
18 The patient-reported secondary outcomes were the Short Form-12 (SF-12) mental and physical  
19  
20 components, Alcohol Use Disorders Identification Test (AUDIT) and Adolescent Drug Involvement  
21  
22 Scale (ADIS) scores. The ADIS also has an additional section on the use of different types of drugs  
23  
24 that enables a score titled the Index of Multiple Drug Use to be scored. This was not a study  
25  
26 outcome but is reported in the results. Secondary outcomes measuring recidivism one-year post-  
27  
28 randomisation were the total number of police records management system (RMS) incidents, the  
29  
30 total number of RMS incidents resulting in being charged or cautioned, the total number of police  
31  
32 national computer (PNC) convictions, whether the participant was charged with a summary or  
33  
34 either-way offence and whether the participant was charged with an indictable only offence. In the  
35  
36 statistical analysis plan it was originally stated the first two recidivism outcomes would be the total  
37  
38 number of RMS incidents plus the total number of PNC convictions up to one-year post-  
39  
40 randomisation and the total number of RMS incidents resulting in being charged or cautioned plus  
41  
42 the total number of PNC convictions. However, on receipt of the RMS and PNC data we found that a  
43  
44 single offence could be classed as both an incident in the RMS data and a conviction in the PNC data,  
45  
46 and hence would lead to double counting when deriving these two recidivism outcomes. It was  
47  
48 therefore decided to separate out the number of PNC convictions and report it as its own outcome.  
49  
50  
51  
52  
53

## 54 ***Patient and public involvement***

55  
56  
57  
58  
59  
60

1  
2  
3 PPI was embedded early on with the help of partners The Hampton Trust (HT). Meetings with young  
4 adults on an HT programme explored various aspects of the study, including importance,  
5 acceptability and feasibility. The groups fed back in detail around the logistics of the study: the  
6 process around consent and randomisation; ways to manage challenges following up the control  
7 arm; and opinion on assessment forms.  
8  
9  
10  
11  
12  
13

14  
15 Once the study was underway, the PPI lead worked with partners to involve young adult  
16 representatives who had been through the Gateway programme and those who had been through  
17 the 'usual process'. Consultation and input from these service users provided a clear understanding  
18 of the challenges and benefits that participants with and without prior experience of the criminal  
19 justice system might face. These PPI representatives worked closely with the PPI lead to develop  
20 consent forms, PISs, and initial information leaflets, plan recruitment strategies and consider the  
21 most effective ways of arranging interviews and qualitative work.  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 There were two public representatives on the Study Steering Committee/Data Monitoring and Ethics  
32 Committee (SSC/DMEC). An ex-offender, working for Hampshire Youth Offenders Team (HYOT) as a  
33 peer mentor and support worker; and a victim advocate, working for a charity for victims of crime.  
34 They represented the voice of the service users and victims at Steering Group meetings, helping the  
35 group reflect on the realities of delivering the programme from the user perspective, reminding the  
36 group of some of the vulnerabilities and needs of this population, and ensuring the views of victims  
37 were considered.  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 These two representatives also worked closely with the study PPI lead, providing strategic input,  
48 advice and guidance throughout, with a particular focus on the logistics of getting the project  
49 underway, reviewing and adapting the protocol. The idea of a recruitment video was conceived by  
50 the ex-offender public representative, and the content was co-created with them.  
51  
52  
53  
54  
55

56  
57 Utilising links established through a local outreach programme, community leaders and members of  
58 the public were consulted. We worked closely with these individuals to ensure we understood the  
59  
60

1  
2  
3 concerns and attitudes of the wider community. Additionally, they were able to provide input to  
4  
5 public facing documentation and materials.  
6  
7

### 8 ***Statistical analysis***

9  
10  
11 It has been suggested that a change of three or more points on the WEMWBS is likely to be  
12  
13 important to individuals, although different statistical approaches provide different estimates  
14  
15 ranging from three to eight points (WEMWBS user guide(13)). Estimates of the standard deviation  
16  
17 also vary between 6 and 10.8(14), with a pooled estimate of 10 across all studies. Assuming 90%  
18  
19 power, 5% statistical significance, a minimal clinically important difference of 5 points on the  
20  
21 WEMWBS and a standard deviation of 10, 266 participants were required. Preliminary figures from  
22  
23 The Hampton Trust's Raising Awareness of Domestic Abuse in Relationships (RADAR) intervention  
24  
25 suggested a drop-out rate of approximately 15%. Assuming a conservative 20% attrition rate, we  
26  
27 aimed to recruit and randomise 334 participants.  
28  
29

30  
31  
32 Analyses were conducted in Stata® version 17 (StataCorp LP; College Station, TX, USA) and followed  
33  
34 a pre-specified statistical analysis plan (SAP) approved by the Study Steering and Data Monitoring  
35  
36 and Ethics Committee prior to the completion of data collection.  
37  
38

39  
40 Version 1.0 of the SAP outlined the planned analyses to assess the effectiveness of the Gateway  
41  
42 intervention, however poor retention and data collection rates made this unfeasible. Version 1.1 of  
43  
44 the SAP removed all reference to formal hypothesis testing and outlined purely descriptive analyses.  
45  
46

47  
48 Continuous measures were summarised using counts, mean, standard deviation, median,  
49  
50 interquartile range (IQR), minimum and maximum. Categorical measures were summarised using  
51  
52 counts and percentages. All participants were analysed according to their randomised group, unless  
53  
54 otherwise stated. The flow of participants from eligibility and randomisation to follow-up and  
55  
56 analysis of the trial was presented in a Consolidated Standards of Reporting Trials (CONSORT) flow  
57  
58 diagram.(15) Reasons for ineligibility and non-consent were given. The number of withdrawals and  
59  
60

1  
2  
3 reasons for withdrawal at each time point were summarised descriptively by randomised treatment  
4 group. Participant demographics were summarised descriptively by randomised treatment group,  
5  
6 both for all participants randomised and participants who provided the primary outcome data for at  
7  
8 least one timepoint. No formal statistical comparisons were undertaken between groups.  
9

10  
11  
12 For those who received Gateway, the number of LINX workshops attended, delivery of LINX  
13  
14 workshops, contacts attempted by the navigator, successful contacts made by the navigator and  
15  
16 total duration of successful contacts were summarised descriptively. For participants who were  
17  
18 cautioned, the conditions attached to each caution were summarised descriptively by whether the  
19  
20 participant received the Gateway conditional caution or a different caution.  
21  
22

23  
24 The primary, secondary and exploratory outcomes were summarised descriptively at each timepoint  
25  
26 by randomised group.  
27

28  
29 Intervention compliance was defined as both minimal compliance and full compliance. Minimal  
30  
31 compliance was met when the participants engaged with their navigator at the initial, midway and  
32  
33 final assessments, attended the two LINX workshops and had not been breached for reoffending  
34  
35 during the duration of the conditional caution. Full compliance was met when the conditions for  
36  
37 minimal compliance were met, and in addition the participant engaged with external agencies  
38  
39 organised by the navigator.  
40  
41

42  
43 The number and proportion of participants informed of their disposal decision after their 4-week  
44  
45 follow-up was due, was presented by randomised treatment group. The number of days between  
46  
47 randomisation and date of disposal were summarised descriptively, alongside whether the  
48  
49 participant attended their 4-week follow-up. The number and proportion of participants in the  
50  
51 intervention group who violated the condition to reoffend was presented. For these participants, the  
52  
53 number for whom discretion was considered before taking the decision to breach was reported.  
54  
55  
56

## 57 58 **Results** 59 60

1  
2  
3 Due to issues with retention of participants and data collection rates, recruitment ended on 13<sup>th</sup>  
4  
5 December 2021, and data was collected for participants due up until 31<sup>st</sup> March 2022.  
6  
7

8  
9 Between the 1<sup>st</sup> of October 2019 and 13<sup>th</sup> December 2021 345 potentially eligible young people were  
10 screened, of which 298 (86.4%) were eligible. Of the 298 eligible, 106 (35.6%) did not consent to the  
11 study. Of these, 77 (72.6%) refused the study but accepted the Gateway caution; 5 (4.7%) refused  
12 the Gateway caution; 2 (1.9%) ran out of prosecution time; and 2 (1.9%) were missed by the  
13 recruiting investigator (reason unknown). There were 20 (18.9%) for whom the reason for non-  
14 consent is unknown. In total, 192 (64.4%) participants were recruited and randomised. One  
15 participant was randomised in error, which led the custody sergeant to non-randomly assign the  
16 participant. This participant is excluded from all further analyses, meaning 191 participants were  
17 randomised and included in the analyses (Gateway 109; usual process 82; Figure 1).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 **INSERT FIGURE ONE HERE**

30 The mean age of participants was 20.8 years (range 18.1-24.8) and 144 (78.7%) were male (Table 1).  
31  
32 The median total number of RMS incidents involved in 1-year pre-randomisation was 6 (3, 13), with  
33 57 (31.5%) participants involved in an RMS incident that led to a caution or charge during this  
34 period. Baseline characteristics of the randomised participants were generally balanced between  
35 groups, except for small imbalances in gender and highest level of education. For participants who  
36 provided a valid WEMWBS score, there was an imbalance in the proportion of participants  
37 previously convicted that was larger than the imbalance observed in all randomised participants.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Participant characteristics presented by allocated group, for all randomised participants and all randomised participants who provided a valid WEMWBS score for at least one timepoint.

	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
<b>Age at randomisation</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Mean (SD)	20.8 (2.0)	20.7 (1.9)	20.8 (1.9)	20.7 (2.0)	20.7 (1.7)	20.7 (1.9)
Median (IQR)	20.3 (19.3, 22.5)	20.4 (19.3, 21.6)	20.4 (19.3, 22.0)	20.2 (19.0, 22.3)	20.5 (19.4, 21.4)	20.3 (19.3, 21.6)
Min, Max	18.1, 24.8	18.1, 24.8	18.1, 24.8	18.1, 24.7	18.1, 24.7	18.1, 24.7
<b>Gender, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Male	87 (82.9)	57 (73.1)	144 (78.7)	51 (79.7)	32 (72.7)	83 (76.9)
Female	18 (17.1)	21 (26.9)	39 (21.3)	13 (20.3)	12 (27.3)	25 (23.1)
<b>Marital status, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Single	62 (93.9)	38 (86.4)	100 (90.9)	60 (93.8)	38 (86.4)	98 (90.7)
Living with partner	4 (6.1)	5 (11.4)	9 (8.2)	4 (6.2)	5 (11.4)	9 (8.3)
Married	0 (0)	1 (2.3)	1 (0.9)	0 (0)	1 (2.3)	1 (0.9)
<b>Ethnicity, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>182 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>108 (100)</b>
White North European	96 (91.4)	75 (96.2)	170 (93.4)	58 (90.6)	44 (100)	102 (94.4)
Black	5 (4.8)	2 (2.6)	7 (3.8)	3 (4.7)	0 (0)	3 (2.8)
Asian	2 (1.9)	1 (1.3)	3 (1.6)	1 (1.6)	0 (0)	1 (0.9)
White South European	1 (1.0)	0 (0)	1 (0.5)	1 (1.6)	0 (0)	1 (0.9)
<b>Highest level of education, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
No qualifications	14 (21.2)	3 (6.8)	17 (15.5)	14 (21.9)	3 (6.8)	17 (15.7)
1-4 GCSEs	20 (30.3)	8 (18.2)	28 (25.5)	20 (31.3)	8 (18.2)	28 (25.9)
More than 5 GCSEs	13 (19.7)	11 (25.0)	24 (21.8)	13 (20.3)	11 (25.0)	24 (22.2)
Apprenticeship	2 (3.0)	5 (11.4)	7 (6.4)	2 (3.1)	5 (11.4)	7 (7.5)
2 or more A-levels	17 (25.8)	15 (34.1)	32 (29.1)	15 (23.4)	15 (34.1)	30 (27.8)
Bachelor's degree or higher	0 (0)	2 (4.5)	2 (1.8)	0 (0)	2 (4.5)	2 (1.9)
<b>IMD quintile (1=most deprived, 5=least deprived), n (%)</b>						
<b>Number with data, n (%)</b>	<b>94 (86.2)</b>	<b>72 (87.8)</b>	<b>166 (86.9)</b>	<b>58 (90.6)</b>	<b>42 (95.5)</b>	<b>100 (92.6)</b>
1	21 (22.3)	20 (27.8)	41 (24.7)	14 (24.1)	14 (33.3)	28 (28.0)
2	25 (26.6)	17 (23.6)	42 (25.3)	14 (24.1)	9 (21.4)	23 (23.0)
3	15 (16.0)	14 (19.4)	29 (17.5)	9 (15.5)	8 (19.0)	17 (17.0)
4	16 (17.0)	7 (9.7)	23 (13.9)	9 (15.5)	4 (9.5)	13 (13.0)
5	17 (18.1)	14 (19.4)	31 (18.7)	12 (20.7)	7 (16.7)	19 (19.0)
<b>Entry route, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>77 (93.9)</b>	<b>182 (95.3)</b>	<b>64 (100)</b>	<b>43 (97.8)</b>	<b>107 (99.1)</b>
Caution	93 (88.6)	72 (93.5)	165 (90.7)	57 (89.1)	42 (97.7)	99 (92.5)
Prosecution	12 (11.4)	5 (6.5)	17 (9.3)	7 (10.9)	1 (2.3)	8 (7.5)
<b>Total number of RMS incidents involved in 1-year pre-randomisation (not including RMS incident that led to study entry)</b>						



	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	10.8 (12.5)	12.9 (25.7)	11.7 (19.2)	9.3 (8.7)	9.0 (9.9)	9.2 (9.2)
Median (IQR)	7 (3, 13)	6 (3, 12)	6 (3, 13)	6 (3, 13)	5 (3, 12)	6 (3, 13)
Min, Max	0, 79	1, 200	0, 200	0, 35	1, 38	0, 38
<b>Total number of RMS incidents leading to charge or caution 1-year pre-randomisation (not including charge or caution that led to study entry)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.6 (1.0)	0.5 (1.3)	0.5 (1.1)	0.6 (1.0)	0.3 (0.6)	0.5 (0.9)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0.5)	0 (0, 1)
Min, Max	0, 4	0, 10	0, 10	0, 4	0, 2	0, 4
<b>Total number of PNC convictions 1-year pre-randomisation</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.5 (0.8)	0.3 (0.5)	0.4 (0.7)	0.4 (0.7)	0.2 (0.5)	0.3 (0.6)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 2	0, 3	0, 2	0, 2	0, 2
<b>Involved in RMS incident that led to caution or charge 1-year pre-randomisation (not including charge or caution that led to study entry), n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	36 (34.6)	21 (27.3)	57 (31.5)	21 (33.3)	11 (25.0)	32 (29.9)
No	68 (65.4)	56 (72.7)	124 (68.5)	42 (66.7)	33 (75.0)	75 (70.1)
<b>PNC conviction 1-year pre-randomisation, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	31 (29.8)	22 (28.6)	53 (29.3)	16 (25.4)	8 (18.2)	24 (22.4)
No	73 (70.2)	55 (71.4)	128 (70.7)	47 (74.6)	36 (81.8)	83 (77.6)
N = number; Min = minimum; Max = maximum; SD = standard deviation; RMS = record management system; PNC = police national computer						

Of the 109 participants randomly assigned Gateway, 104 (95.4%) received Gateway with four of the remaining five receiving a standard caution. Of the 81 (98.8%) participants who were randomly assigned to and received usual process, 76 (93.8%) entered the study via the caution route i.e. received a different conditional caution. There were 18 (17.1%) who received a Gateway caution with the additional condition of providing compensation, while 5 (4.8%) were required to write a letter of apology the victim. Of those who received a simple or conditional caution, the most

1  
2  
3 common conditions attached were compensation (n=20; 25.0%), attending a drug diversion course  
4  
5 (n=16; 20.0%) and attending a victim awareness course (n=14; 17.5%).  
6  
7

8 Of the 105 participants who received Gateway, data on number of LINX sessions attend was received  
9  
10 for 101 (96.2%), of which 88 (87.1%) attended both sessions, 1 (1.0%) attended one session, 8 (7.9%)  
11  
12 did not attend any sessions, while 4 (4.0%) could not attend due to the COVID-19 pause. Of those  
13  
14 who attended at least one workshop, 45 (56.3%) attended a face-to-face workshop while 35 (43.8%)  
15  
16 had the workshop delivered via the telephone. The median number of successful contacts made by  
17  
18 the navigator to the participant was 19 (IQR 15 to 31). For each participant the total duration of  
19  
20 successful contacts was calculated, the median of which was 626.5 minutes (IQR 380, 978). Further  
21  
22 information on the delivery of Gateway and usual process is presented in Appendix A in the  
23  
24 supplementary materials.  
25  
26  
27  
28

29 At the primary endpoint of one-year post-randomisation, 43 (22.5%) case report forms (CRFs) were  
30  
31 returned (Gateway 27,24.8%; usual process 16,19.5%) (Figure 1). At 4-weeks post-randomisation 94  
32  
33 (49.2%) CRFs were returned (Gateway 58, 53.2%; usual process 36, 43.9%) while at 16 weeks post-  
34  
35 randomisation 95 (49.7%) (Gateway 56, 51.4%; usual process 39,47.6%). The WEMWBS, SF-12,  
36  
37 AUDIT and ADIS data for one participant in the Gateway group was excluded at week 4 due to the  
38  
39 questionnaire being completed too early. At week 16 the data for two participants in the Gateway  
40  
41 group were excluded due to the questionnaires being completed too late.  
42  
43  
44

45 Valid participant-reported outcome data was provided by 96 (50.3%) participants at the 4-week  
46  
47 follow-up, 93 (48.7%) participants at the 16-week follow-up and 43 (22.5%) participants at the 1-year  
48  
49 follow-up (Gateway 56, 51.4%; usual process 39, 47.6%. Descriptive summaries of the primary and  
50  
51 secondary outcomes are provided in Table 2 and Table 3 respectively.  
52  
53  
54

55 There were 129 (67.5%) participants who had reached the one-year follow-up before their RMS data  
56  
57 was extracted by HC on the 23<sup>rd</sup> of June 2022, while 125 (65.4%) reached the one-year follow-up  
58  
59 before their PNC data was extracted. Ten participants who withdrew before or after stage 2 consent,  
60

declined stage 2 consent or lost mental capacity did not have their RMS and PNC data reported. Of the 32 participants in the Gateway group who had been in the study less than one year, 2 (6.3%) had been charged with a summary or either-way offence, while of the 24 participants in the usual process group, 2 (8.3%) had been charged. For the 56 participants who had been in the study less than one year, the mean time between date of randomisation and date of data extraction was 286.9 days (SD 56.7 days). Table 4 gives descriptive summaries of the recidivism outcomes.

**Table 2:** The WEMWBS score at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	44.1 (9.6)	44.9 (7.2)
Median (IQR)	45 (38, 52)	44 (41, 49)
Min, Max	19, 61	28, 62
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	48.6 (9.9)	46.0 (8.5)
Median (IQR)	49 (42, 55)	47 (40, 53)
Min, Max	27, 67	30, 60
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.4 (9.7)	45.7 (7.0)
Median (IQR)	49 (41, 54)	45.5 (41.5, 50.5)
Min, Max	29, 68	28, 58

**Table 3:** Secondary and exploratory participant-reported outcomes at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>SF-12 Mental Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	42.4 (12.0)	43.5 (9.7)
Median (IQR)	43.6 (35.7, 53.1)	43.8 (36.8, 51.9)
Min, Max	15.1, 58.8	22.1, 58.8
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	47.7 (7.6)	45.0 (9.1)
Median (IQR)	47.7 (41.7, 54.6)	45.8 (38.7, 52.7)
Min, Max	34.3, 58.8	20.7, 58.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	47.5 (7.5)	46.1 (8.6)
Median (IQR)	47.7 (39.5, 54.6)	47.5 (44.4, 51.8)
Min, Max	34.3, 58.8	20.7, 58.1
<b>SF-12 Physical Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	54.5 (5.3)	52.8 (6.7)
Median (IQR)	55.5 (53.7, 57.4)	55.2 (51.2, 56.8)
Min, Max	36.8, 63.9	30.8, 59.2
<b>Week 16</b>		

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	52.5 (6.4)	53.4 (5.7)
Median (IQR)	54.5 (51.7, 56.0)	55.2 (52.4, 56.9)
Min, Max	26.1, 59.4	38.0, 60.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	51.9 (7.9)	53.5 (6.3)
Median (IQR)	54.5 (51.7, 56.5)	55.3 (52.5, 58.2)
Min, Max	26.1, 59.4	38.0, 58.9
<b>AUDIT</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	12.9 (9.2)	11.2 (7.5)
Median (IQR)	11 (5, 19)	10.5 (5.5, 16.5)
Min, Max	0, 34	0, 28
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	11.6 (8.1)	11.6 (8.7)
Median (IQR)	9.5 (5, 15)	10 (4, 16)
Min, Max	0, 32	0, 36
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	11.1 (8.5)	13.3 (8.3)
Median (IQR)	8 (5, 20)	12.5 (8, 17)
Min, Max	0, 30	1, 30
<b>ADIS</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	46.9 (33.6)	45.1 (36.5)
Median (IQR)	38 (25, 59)	37.5 (12, 76.5)
Min, Max	0, 137	0, 111
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	40.9 (36.3)	37.2 (38.2)
Median (IQR)	36.5 (15, 52)	31 (0, 67)
Min, Max	0, 137	0, 111
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.7 (36.1)	50.5 (39.0)
Median (IQR)	40 (23, 68)	38.5 (20.5, 86)
Min, Max	0, 134	0, 111
<b>Accommodation status (exploratory), n (%)</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Homeless	8 (14.0)	3 (8.3)
Not homeless	49 (86.0)	33 (91.7)
<b>Year 1, n (%)</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Homeless	3 (11.1)	0 (0)
Not homeless	24 (88.9)	15 (100)

**Table 4:** Recidivism outcomes presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>RMS incidents involved in up to one-year post-randomisation</b>		
Number with data, n (%)	74 (67.9)	55 (67.1)
Mean (SD)	9.3 (12.2)	12.2 (23.7)
Median (IQR)	5 (1, 14)	5 (1, 11)
Min, Max	0, 61	0, 132
<b>Total number of RMS incidents resulting in being classed as a suspect and charged/cautioned up to one-year post-randomisation</b>		
Number with data, n (%)	74 (67.9)	55 (67.1)
Mean (SD)	0.4 (1.2)	0.8 (2.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 7	0, 20
<b>Total number of PNC convictions up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (64.6)
Mean (SD)	0.4 (0.8)	0.4 (0.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 5
<b>Charged with a 'summary' or 'either way' offence up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (63.9)
Charged	19 (26.4)	16 (30.2)
Not charged	53 (73.6)	37 (69.8)
<b>Charged with an 'indictable only' offence up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (64.6)
Charged	0 (0)	0 (0)
Not charged	72 (100)	53 (100)

Of the 105 participants randomly allocated to the Gateway conditional caution who did not withdraw before stage 2 or withdraw stage 2 consent, 81 (77.1%) met the definition for minimal compliance. Thirteen participants did not meet minimal compliance due to not attending the two LINX sessions, six did not meet minimal compliance due to breaching the condition to not reoffending during the period of the caution and five were given usual process despite being randomly assigned to the Gateway conditional caution.

No participants were withdrawn from the Gateway conditional caution because they failed to engage with referral agencies identified by the navigator, therefore the number of participants meeting full compliance was 81 (77.1%).

1  
2  
3 Of the 191 randomised participants, 15 (7.9%) were informed of their disposal decision after their 4-  
4 week follow-up was due (Gateway 12, 11.1%; usual process 3, 3.7%; see Appendix B of the  
5 supplementary materials).  
6  
7  
8

9  
10 Of the 105 participants who received the Gateway conditional caution who did not withdraw before  
11 stage 2 or withdraw stage 2 consent, 8 (7.6%) reoffended during the period of the conditional  
12 caution. There were two (25.0%) participants for whom discretion was applied before taking the  
13 decision that they were in breach of the condition not to reoffend. The remaining 6 (75.0%) were  
14 referred back to the original investigator. Due to the risk of data disclosure further information is not  
15 provided here.  
16  
17  
18  
19  
20  
21  
22  
23

24 Information on the Index of Multiple Drug Use, adverse childhood experiences and the health  
25 economic data are presented in appendices C, D and E respectively.  
26  
27  
28  
29

### 30 **Discussion**

31  
32 The Gateway study is the first RCT in the UK police setting to have a health-related primary outcome  
33 requiring consent and individual data collection rather than prioritising criminal justice data on  
34 recidivism. We have demonstrated that is possible, using a novel two-stage consent process, to  
35 recruit and randomise young people who have committed a minor offence to an RCT in the police  
36 setting. Out of court disposals issued by the police such as conditional cautions for less serious  
37 offences have been used in practice for over a decade.<sup>(6)</sup> Evaluations of such interventions have  
38 been carried out, including Cautioning and Relationship Abuse (CARA) (9), Checkpoint (5) and  
39 Operation Turning Point<sup>(9)</sup> to assess their impact on recidivism. Our study differed from these  
40 examples in that our primary outcome was health related. For ethical reasons therefore we needed  
41 participant consent prior to randomisation. A considerable amount of additional work to set up and  
42 for the investigators to administer at a time of stress for potential participants. We were only able to  
43 recruit because of the close collaboration between the research team and Hampshire Constabulary.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 A key limitation of the study is that due to high attrition rates, the study was ended early and an  
7  
8 assessment of the effectiveness of the Gateway intervention compared to usual process could not  
9  
10 be completed. Similar issues with the follow-up and the collection of health data have been found in  
11  
12 other community-based studies in disadvantaged populations, especially those with young people.  
13  
14 (16, 17) We implemented numerous strategies to overcome our issues with retention including a  
15  
16 telephone call reminder about the study from the HC Gateway Project Officer before stage 2 consent  
17  
18 was due. Our public involvement work with vulnerable young people resulted in valuable  
19  
20 suggestions, which we implemented, including changing the wording on participant facing  
21  
22 information and creating a video explaining the study. We also increased the value of the shopping  
23  
24 gift cards on offer for return of outcome data. In addition, we put into place strategies to improve  
25  
26 recruitment, including expansion of the study catchment area and following up the non-screening of  
27  
28 a potentially eligible participant with the recruiting police staff member to ascertain the factors that  
29  
30 led to this. However, we were unable to solve the barrier presented by out-of-date or invalid contact  
31  
32 details, as well as the lack of response by the participants to contact attempts by the researchers.  
33  
34  
35  
36  
37  
38 The groups were generally well balanced in terms of characteristics and percentage providing data,  
39  
40 and allocation did not appear to make any difference to level of engagement. Participants who took  
41  
42 part in data collection interviews completed all parts of the WEMWBS, SF-12, AUDIT and ADIS  
43  
44 instruments at all time points. This suggests that the questions were not overly burdensome or  
45  
46 intrusive and that telephone interviews were acceptable to those willing to share a valid telephone  
47  
48 number.  
49  
50

51  
52 The challenges in recruiting and retaining participants that we faced, and the strategies we put in  
53  
54 place to overcome them will help researchers planning and carrying out future studies with this  
55  
56 population. We have also provided a benchmark for attrition in this population and setting, which  
57  
58  
59  
60

1  
2  
3 indicates that further work is needed to identify ways to facilitate engagement between researchers  
4  
5 and this vulnerable population.  
6  
7

8 A regression discontinuity design (RDD) may be a pragmatic solution to the recruitment issues  
9  
10 encountered by the Gateway trial,(18) that has been used before in the criminal justice setting.(19,  
11  
12 20) The RDD is a quasi-experimental design that allocates participants to intervention or control  
13  
14 according to their score on a continuous baseline variable, with the outcome being a continuous  
15  
16 measure. If there is no effect of the intervention, then the regression plots of the allocation variable  
17  
18 against the outcome of interest will be smooth with no interruption at the point of allocation on the  
19  
20 pre-test variable. However, if the intervention is effective then there will be a change or  
21  
22 discontinuity in the regression slope at the point of allocation.  
23  
24  
25

26  
27 For example, in the criminal justice setting a prospective RDD could use a standardised offender risk  
28  
29 score to assign treatment, with participants scoring above a certain threshold being allocated to the  
30  
31 intervention, which is probably more logical and acceptable to staff and offenders than the use of  
32  
33 randomisation. A prospective design would allow for outcomes that may not be routinely collected,  
34  
35 but are relevant to health care professionals and the police, to be collected as part of the study. In  
36  
37 theory, the RRD would mitigate against selection bias by assuming that measurement error around  
38  
39 the threshold point produces equivalent groups.  
40  
41  
42

### 43 **Conclusion**

44  
45  
46 We have demonstrated that it is possible to recruit and randomise this study population in a police  
47  
48 setting, but recruitment and retention estimates should be conservative. However, more work is  
49  
50 needed to identify strategies to improve retention rates when carrying out research with this  
51  
52 underserved population.  
53  
54

### 55 **List of abbreviations**

ADIS	Adolescent Drug Involvement Scale
AUDIT	Alcohol Use Disorders Identification Test



CONSORT	Consolidated Standards of Reporting Trials
CRF	Case Report Form
CTU	Clinical trials unit
DMEC	Data monitoring and ethics committee
EME	Efficacy and mechanism evaluation
ERGO	Ethics and Research Governance online
HC	Hampshire Constabulary
HTA	Health technology assessment
HRA	Health Research Authority
HT	Hampton Trust
HYOT	Hampshire Youth Offenders Team
IQR	Interquartile range
ISRCTN	International Standard Randomised Controlled Trial Number
NIHR	National Institute of Health Research
OCBI	Out-of-court community-based intervention
OOCD	Out-of-court-disposal
PNC	Police National Computer
PPI	Patient and public involvement
RCT	Randomised controlled trial
REC	Research Ethics Committee
RDD	Regression discontinuity design
RMS	Record Management System
SAP	Statistical Analysis Plan
SF-12	12-Item Short Form Health Survey
SSC	Study steering committee
SD	Standard deviation
UoS	University of Southampton
WEMWBS	Warwick-Edinburgh Mental Wellbeing Scale
YTU	York Trials Unit

### ***Ethics approval and consent to participate***

The study protocol, all associated study documents and amendments were approved by the University of Southampton Ethics and Research Information Governance Board (ERGO ID: 31911).

The outline proposal was submitted to the Hampshire Constabulary Ethics Committee, who agreed to support the study. The following external ethics boards confirmed their approval was not

1  
2  
3 required: HRA Research Ethics Service, Social Care REC approval, Her Majesty Prison Probation  
4  
5 Services.

### 8 ***Availability of data and materials***

10  
11 Data will be made available on reasonable request to the study statistician  
12  
13 ([alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)), who will consult with the chief investigator and trial management group  
14  
15 before a final decision is made.

### 18 ***Competing interests***

20  
21 Catherine Hewitt was Deputy Chair of the NIHR HTA commissioning board, NIHR CTU Standing  
22  
23 Advisory Committee, HTA Post-Funding Committee teleconference and the HTA Funding Committee  
24  
25 Policy Group. James Raftery is a member of the NIHR Editorial Board for HTA and EME. Julie Parkes is  
26  
27 Director of Training, UK Faculty of Public Health. There are no other declared competing interests.  
28  
29

### 32 ***Funding***

34  
35 The Gateway trial was funded by the National Institute of Health Research (NIHR) Public Health  
36  
37 Research Programme (award ID: 16/122/20).  
38

### 40 ***Authors' contributions***

42  
43 **Alex Mitchell**, (<https://orcid.org/0000-0001-9311-2092>) (Statistician, Health Sciences), contributed  
44  
45 to the overall study design, wrote the statistical analysis plan, conducted the statistical analysis,  
46  
47 contributed to writing and editing the manuscript.  
48

49  
50 **Alison Booth**, (<https://orcid.org/0000-0001-7138-6295>) (Senior Research Fellow, Health Sciences)  
51  
52 was a co-investigator, contributed to conceptualisation and design, funding acquisition, protocol  
53  
54 development, and was trial manager for the conduct and delivery of the trial, site setup and data  
55  
56 management, manuscript writing and editing.  
57  
58  
59  
60

1  
2  
3 **Sara Morgan**, (<https://orcid.org/0000-0001-8346-6655>) (Lecturer, Public Health) was a co-  
4 investigator, contributed to conceptualisation and design, funding acquisition, protocol  
5 development, conduct and delivery of the trial and qualitative evaluation, data acquisition,  
6 qualitative analysis and manuscript commenting.  
7  
8  
9  
10

11  
12 **Inna Walker**, (<https://orcid.org/0000-0002-8460-8130>) (Clinical Research Fellow, quantitative and  
13 qualitative researcher) contributed to protocol development and study design, conduct and delivery  
14 of the trial and qualitative evaluation, data acquisition, qualitative analysis, manuscript commenting.  
15  
16  
17  
18

19  
20 **Megan Barlow-Pay**, (<https://orcid.org/0000-0003-1473-2096>) (Patient and Public Involvement and  
21 Engagement (PPIE) and researcher) was the PPI lead for the study, undertook PPI work, contributed  
22 to study design and conduct, quantitative data collection qualitative data collection and analysis, and  
23 commenting on the manuscript.  
24  
25  
26  
27  
28

29  
30 **Caroline Chapman**, (<https://orcid.org/0000-0002-6498-5932>) (Sergeant, Gateway Project Support  
31 Officer for Hampshire Constabulary) contributed to protocol development, trial conduct, setting up  
32 of sites, data acquisition and checking, commented on the manuscript.  
33  
34  
35  
36

37  
38 **Ann Cochrane**, (<https://orcid.org/0000-0002-1502-6719>) (Trial Coordinator, Health Sciences),  
39 contributed to protocol development, trial conduct, setting up of sites, data acquisition and  
40 processing and commented on the manuscript.  
41  
42  
43  
44

45  
46 **Emma Filby**, (<https://orcid.org/0000-0002-1090-1123>) (Data administrator, Health Sciences)  
47 contributed to the study conduct, project administration, data management, and commented on the  
48 manuscript.  
49  
50  
51

52  
53 **Jenny Fleming**, (<https://orcid.org/0000-0002-7913-3345>) (Professor in Criminology, qualitative  
54 methodologist) was a co-investigator contributing to conceptualisation and design, funding  
55 acquisition, protocol development, trial conduct, and commenting on the manuscript.  
56  
57  
58  
59  
60

1  
2  
3 **Catherine Hewitt**, (<https://orcid.org/0000-0002-0415-3536>) (Professor in Statistics, Health Sciences)  
4  
5 was a co-investigator, she contributed to conceptualisation and design, funding acquisition, protocol  
6  
7 development, provided oversight of trial conduct and the statistical analysis, and commented on the  
8  
9 manuscript.  
10

11  
12  
13 **James Raftery**, (<https://orcid.org/0000-0003-1094-8578>) (Professor in Health Economics), as a  
14  
15 coinvestigator, contributed to conceptualisation and design, funding acquisition, protocol  
16  
17 development, trial conduct, and commented on the manuscript.  
18

19  
20 **David Torgerson**, (<https://orcid.org/0000-0002-1667-4275>) (Professor, Director of York Trials Unit)  
21  
22 as a co-investigator, contributed to conceptualisation and design, protocol development, funding  
23  
24 acquisition, trial conduct, and commented on the manuscript.  
25

26  
27  
28 **Lana Weir**, (<https://orcid.org/0000-0003-4730-7969>) (Trial Coordinator, qualitative researcher),  
29  
30 contributed to project administration, data acquisition, qualitative analysis, manuscript commenting.  
31

32  
33 **Julie Parkes**, (<https://orcid.org/0000-0002-6490-395X>) (Professor in Public Health) was the Chief  
34  
35 Investigator, and contributed to the conceptualisation and design, funding acquisition, protocol  
36  
37 development, trial conduct, manuscript commenting.  
38

### 39 **Acknowledgements**

40  
41  
42 We would like to acknowledge and thank all those who contributed to the study.  
43

44  
45 All the young people who took part in the trial and associated interviews.  
46

47  
48 Gateway Navigators provided by No Limits and Southampton City Council who delivered the  
49  
50 intervention; Debbie Willis, Children and Young People's Services Manager and colleagues at The  
51  
52 Hampton Trust, responsible for LINX; those organisations taking referrals from the Navigators: The  
53  
54 Prince's Trust, Two Saints (Housing) and the Community Mental Health Teams across Hampshire and  
55  
56 Isle of Wight, as well as others. Members of the Trial Management Group (TMG) who contributed at  
57  
58 various stages of the study: Inspector Benjamin Taylor (Hampshire Constabulary), Rosanna Orlando  
59  
60

1  
2  
3 (Health Economist), Anthony Quinn (Qualitative Researcher), Inspector Stuart Baker (Hampshire  
4  
5 Constabulary).

6  
7  
8 Those who supported the study and funded the intervention: Office of Police and Crime  
9  
10 Commissioner (PCC) supporting the PCC for Hampshire and Isle of Wight, and senior management at  
11  
12 Hampshire Constabulary

13  
14  
15 All the police investigators who underwent training and recruited participants into the trial.

16  
17  
18 Members of the Public Participation Panel (PPP), and all the members of the public who contributed  
19  
20 during the development and delivery of the study.

21  
22  
23 The University of Southampton for being the study sponsor and to members of the Study Steering  
24  
25 and Data Monitoring and Ethics Committee for their advice and support.

## 26 27 28 29 **References**

- 30  
31  
32 1. Alcorn T. Rethinking mental health care for young offenders. *The Lancet*.  
33 2014;383(9925):1283-4.
- 34 2. Underwood LA, Washington A. Mental Illness and Juvenile Offenders. *International Journal*  
35 *of Environmental Research and Public Health*. 2016;13(2):228.
- 36 3. Lauren Bennett BB, Rose Dowling and Tracy Shildrick. *Broke, but not broken*. Revolving  
37 *Doors Agency*; 2021.
- 38 4. Britton S. *Improving Responses To Young Adults*. In *Transition to Adulthood Alliance*. UK;  
39 2014.
- 40 5. Petrosino A, Turpin-Petrosino C, Guckenberg S. Formal system processing of juveniles:  
41 *Effects on delinquency*. *Campbell Systematic Review 2010*(DOI: 10.4073/csr.2010.1).
- 42 6. Weir K, Routledge G, Kilili S. Checkpoint: An innovative programme to navigate people away  
43 from the cycle of reoffending: Implementation phase evaluation. *Policing: A Journal of Policy and*  
44 *Practice*. 2021;15(1):508-27.
- 45 7. Neyroud P. *Out of court disposals managed by the police: a review of the evidence*.  
46 Commissioned by the National Police Chief's Council of England and Wales University of Cambridge.  
47 2018.
- 48 8. Britton S. *PCC spotlight: Young Adults (18-24) in contact with police and criminal justice*  
49 *services*. UK; 2015.
- 50 9. Neyroud P, Slothower M. *Operation Turning Point: interim report on a randomised trial in*  
51 *Birmingham, UK*. Cambridge; 2013.
- 52 10. Wilson DB, Brennan I, Olaghery A. Police-initiated diversion for youth to prevent future  
53 *delinquent behavior: A systematic review*. *Campbell Systematic Reviews*. 2018;14(1):1-88.
- 54 11. Cochrane A, Booth A, Walker I, Morgan S, Mitchell A, Barlow-Pay M, et al. Examining the  
55 effectiveness of Gateway—an out-of-court community-based intervention to reduce recidivism and  
56 improve the health and well-being of young adults committing low-level offences: study protocol for  
57 a randomised controlled trial. *Trials*. 2021;22(1):939.
- 58  
59  
60

12. Strang H, Sherman L, Ariel B, Chilton S, Braddock R, Rowlinson T, et al. Reducing the Harm of Intimate Partner Violence: Randomized Controlled Trial of the Hampshire Constabulary CARA Experiment. *Camb J Evid Based Polic*. 2017.
13. Stewart-Brown S, K. J. Warwick-Edinburgh Mental Well-being Scale (WEMWBS): User Guide. University of Warwick; 2008.
14. Maheswaran H, Weich S, Powell J, Stewart-Brown S. Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): Group and individual level analysis. *Health and Quality of Life Outcomes*. 2012;10(1):156.
15. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.
16. Lankenau SE, Sanders B, Hathazi D, Bloom JJ. Recruiting and retaining mobile young injection drug users in a longitudinal study. *Subst Use Misuse*. 2010;45(5):684-99.
17. Patel MX, Doku V, Tennakoon L. Challenges in recruitment of research participants. *Advances in Psychiatric Treatment*. 2003;9(3):229-38.
18. Reichardt CS. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. *JSTOR*; 2002.
19. Mitchell O. A Policy Evaluation of Home Detention Sentencing: Evidence from New Zealand: Auckland University of Technology; 2019.
20. Rhodes W, Jalbert SK. Regression discontinuity design in criminal justice evaluation: an introduction and illustration. *Eval Rev*. 2013;37(3-4):239-73.




Figure 1: CONSORT diagram demonstrating the progression of participants through the trial.

481x695mm (38 x 38 DPI)

## Appendix A: Delivery of Gateway and usual process

**Table 1:** Conditions attached to cautions, presented by whether the participant received a Gateway conditional caution or a caution forming part of usual process (either a simple caution or a different conditional caution).

	<b>Gateway conditional caution (n=105)</b>	<b>Usual process (n=80)</b>
<b>Conditions attached (multiple conditions possible), n (%)</b>		
Standard Gateway conditions (no additional conditions added)	85 (81.0)	NA
None (simple caution)	NA	5 (6.3)
Compensation	18 (17.1)	20 (25.0)
Letter of apology	5 (4.8)	10 (12.5)
Victim awareness course	0 (0)	14 (17.5)
Alcohol diversion course	0 (0)	11 (13.8)
Drugs diversion course	0 (0)	16 (20.0)
Not to enter specific premises	0 (0)	1 (1.3)
Fine	0 (0)	5 (6.3)
Women and Desistance Empowerment programme	0 (0)	9 (11.3)
Restorative justice	0 (0)	0 (0)

**Table 2:** Information on delivery of the Gateway intervention.

	<b>Received Gateway conditional caution (n=105)</b>
<b>LINX workshops attended (supplemented with change of status data)</b>	
<b>Number with data, n (%)</b>	<b>101 (96.2)</b>
0 (Did not attend LINX sessions due to COVID-19 pause)	4 (4.0)
0 (participant chose to not attend LINX sessions)	8 (7.9)
1 (participant chose not to attend LINX session)	1 (1.0)
2	88 (87.1)
<b>Delivery of LINX workshops</b>	
<b>Number with data, n (% of those who attended at least one workshop)</b>	<b>80 (89.9%)</b>



Face-to-face	45 (56.3)
Telephone	35 (43.8)
<b>Contacts attempted by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	52.8 (25.0)
Median (IQR)	42 (39, 63)
Min, Max	22, 168
<b>Successful contacts made by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	26.0 (20.7)
Median (IQR)	19 (15, 31)
Min, Max	0, 108
<b>Total duration of successful contacts, minutes</b>	
<b>Number with data, n (%)</b>	<b>70 (66.7)</b>
Mean (SD)	761.5 (594.6)
Median (IQR)	626.5 (380, 978)
Min, Max	36, 2785

## Appendix B: Participants informed of their disposal decision after their 4-week follow-up was due

**Table 3:** Information on time between randomisation and disposal decision and whether the 4-week follow-up was attended, for those informed of their disposal decision after the 4-week follow-up was due.

	<b>Gateway conditional caution (n=12)</b>	<b>Usual process (n=3)</b>	<b>Total (n=15)</b>
<b>Time between randomisation and disposal, days</b>			
<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>
Mean (SD)	49.6 (18.1)	NA	NA
Median (IQR)	42 (34.5, 67.5)	NA	NA
Min, Max	29, 77	NA	NA
<b>Attended 4-week follow-up, n (%)</b>			
<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>

Yes	8 (66.7)	NA	NA
No	4 (33.3)	NA	NA

## Appendix C: Index of Multiple Drug Use

**Table 4:** Index of Multiple Drug Use presented at 4-weeks, 16-weeks and 1-year post randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	23.3 (6.4)	21.3 (5.0)
Median (IQR)	22 (18, 27)	21.5 (16.5, 25)
Min, Max	15, 42	15, 31
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	23.3 (7.5)	22.3 (5.9)
Median (IQR)	21 (17, 27)	22 (16, 25)
Min, Max	15, 47	15, 38
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	25.2 (7.7)	25.8 (6.3)
Median (IQR)	23 (18, 31)	25.5 (21, 28.5)
Min, Max	16, 41	16, 38

## Appendix D: Adverse childhood experiences

**Table 5:** Adverse childhood experiences reported at 16 weeks post-randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Number of adverse childhood experiences</b>		
<b>Number with data (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	3.0 (2.6)	3.6 (3.0)
Median (IQR)	2 (1, 5)	4 (1, 5)
Min, Max	0, 10	0, 11

## Appendix E: Health economic analysis

**Table 6:** Health economic data at 4-weeks, 16-weeks and 1-year post-randomisation, presented by group.

	<b>4-weeks post- randomisation</b>	<b>16-weeks post- randomisation</b>	<b>1-year post- randomisation</b>

	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Employed in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Yes	31 (54.4)	16 (44.4)	31 (57.4)	19 (48.7)	16 (59.3)	11 (68.8)
No	26 (45.6)	20 (55.6)	23 (42.6)	20 (51.3)	11 (40.7)	5 (31.3)
<b>Number of times visited GP in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.4 (0.7)	0.5 (1.0)	0.4 (1.0)	0.5 (0.9)	0.5 (1.0)	1.3 (2.6)
Median (IQR)	0 (0, 1)	0 (0, 0.5)	0 (0, 0)	0 (0, 0)	0 (0, 1)	1 (0, 1)
Min, Max	0, 3	0, 4	0, 5	0, 3	0, 4	0, 10
<b>Number of times used drug/alcohol services in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.3 (0.9)	0.3 (1.7)	0.4 (1.2)	0.1 (0.4)	0.2 (0.8)	0.4 (1.1)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 10	0, 5	0, 2	0, 4	0, 4
<b>Number of times visited accident and emergency in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.9)	0.1 (0.2)	0.1 (0.3)	0 (0.2)	0.6 (1.9)	0.2 (0.6)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 6	0, 1	0, 2	0, 1	0, 10	0, 2
<b>Number of times admitted to hospital as inpatient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.1 (0.3)	0 (0)	0.1 (0.3)	0 (0)	0.3 (1.0)	0 (0)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 2	0, 0	0, 2	0, 0	0, 4	0, 0
<b>Number of times used community mental health</b>						

<b>team in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>35 (2.7)</b>	<b>53 (48.6)</b>	<b>38 (46.3)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.8)	0.2 (0.7)	0.2 (0.6)	1.1 (4.9)	0.4 (1.1)	0.5 (1.2)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 3	0, 3	0, 30	0, 4	0, 4
<b>Number of times used psychiatric services as in-patient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0 (0.2)	0 (0.2)	0 (0)	0.2 (1.0)	0 (0.2)	0.1 (0.3)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 1	0, 1	0, 0	0, 6	0, 1	0, 1
<b>Used the following prescribed medications in previous month, n (%)</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (25.0)</b>	<b>16 (19.3)</b>
Amitriptyline	1 (1.8)	0 (0)	1 (1.9)	0 (0)	2 (7.4)	0 (0)
Aripirazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cerelle	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Citalopram	3 (5.3)	1 (2.8)	1 (1.9)	2 (5.1)	1 (3.7)	0 (0)
Co-codamol	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Codeine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Cyclizine	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Diazepam	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Doxycycline	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Inhaler	0 (0)	4 (11.1)	5 (9.3)	2 (5.1)	1 (3.7)	0 (0)
Escitalopram	1 (1.8)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Fluoxetine	3 (5.3)	1 (2.8)	0 (0)	2 (5.1)	0 (0)	0 (0)
Quetiapine	2 (3.5)	1 (2.8)	0 (0)	0 (0)	0 (0)	1 (6.3)
Lamotrigine	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Lymecycline	0 (0)	2 (5.6)	0 (0)	1 (2.6)	0 (0)	0 (0)
Macrogol 3350	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Melatonin	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Methadone	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Mirtazapine	2 (3.5)	0 (0)	2 (3.7)	0 (0)	1 (3.7)	1 (6.3)
Naproxen	1 (1.8)	0 (0)	2 (3.7)	0 (0)	0 (0)	0 (0)
Omeprazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ondansetron	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Olanzapine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Phenergan	0 (0)	2 (5.6)	0 (0)	0 (0)	0 (0)	0 (0)

Prednisolone	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Pregabalin	0 (0)	1 (2.8)	1 (1.9)	0 (0)	0 (0)	0 (0)
Prochlorperazine maleate	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Promethazine hydrochloride	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Propranolol hydrochloride	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Quetiapine	2 (3.5)	0 (0)	4 (7.4)	3 (7.7)	2 (7.4)	0 (0)
Ramipril	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Risperidone	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Salbutamol	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6.3)
Sertraline	3 (5.3)	4 (11.1)	7 (13.0)	5 (12.8)	2 (7.4)	2 (12.5)
Prochlorperazine	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Tacrolimus	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Venlafaxine	1 (1.8)	0 (0)	0 (0)	1 (2.6)	1 (3.7)	0 (0)
Vortioxetine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Reason for using prescribed medications in previous month, n (%)</b>						
<b>Number with data (% of those who reported using a medication)</b>						
Acne	0 (0)	3 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)
Anterior cruciate ligament injury	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
ADHD	1 (5.0)	1 (6.7)	1 (4.8)	0 (0)	0 (0)	0 (0)
Anxiety	7 (35.0)	7 (46.7)	4 (19.0)	2 (14.3)	2 (25.0)	2 (28.6)
Asthma	1 (5.0)	4 (26.7)	5 (23.8)	2 (14.3)	1 (12.5)	1 (14.3)
Back pain	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Blood pressure	0 (0)	0 (0)	0 (0)	0 (0)	1 (12.5)	0 (0)
Depression	11 (55.0)	7 (46.7)	8 (38.1)	3 (21.4)	5 (62.5)	2 (28.6)
Ear infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Gastroparesis	1 (5.0)	0 (0)	1 (4.8)	0 (0)	1 (12.5)	0 (0)
Heroin addiction	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Hypertension	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Immune	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)

system						
suppression						
post-kidney						
transplant						
Inflammation	1 (5.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Insomnia	2 (10.0)	1 (6.7)	0 (0)	1 (7.1)	1 (12.5)	0 (0)
Mood	2 (10.0)	1 (6.7)	3 (14.3)	1 (7.1)	1 (12.5)	0 (0)
stabilisation						
Nail infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Nausea	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Pain relief	0 (0)	0 (0)	2 (9.5)	0 (0)	1 (12.5)	0 (0)
Panic attacks	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
Psychosis	2 (10.0)	1 (6.7)	1 (4.8)	0 (0)	1 (12.5)	1 (14.3)
PTSD	0 (0)	2 (13.3)	0 (0)	0 (0)	0 (0)	0 (0)



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	4
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	2, 5, 7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	8, 9
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

1		assessing outcomes) and how	
2	11b	If relevant, description of the similarity of interventions	N/A
3	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes
4		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses
5			
6	<b>Results</b>		
7	Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and
8	diagram is strongly		were analysed for the primary outcome
9	recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons
10			
11			
12	Recruitment	14a	Dates defining the periods of recruitment and follow-up
13		14b	Why the trial ended or was stopped
14			
15	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group
16	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was
17			by original assigned groups
18			
19	Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its
20	estimation		precision (such as 95% confidence interval)
21		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended
22	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing
23			pre-specified from exploratory
24			
25	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
26			
27	<b>Discussion</b>		
28	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
29	Generalisability	21	Generalisability (external validity, applicability) of the trial findings
30	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
31			
32	<b>Other information</b>		
33	Registration	23	Registration number and name of trial registry
34	Protocol	24	Where the full trial protocol can be accessed, if available
35	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders
36			

37 Citation: Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine. 2010;8:18.  
 38 © 2010 Schulz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits  
 39 unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

40 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend  
 41 reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional  
 42 extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).



# BMJ Open

## Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young adults committing low-level offences: a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081179.R2
Article Type:	Original research
Date Submitted by the Author:	08-Apr-2024
Complete List of Authors:	Mitchell, Alex; University of York, Department of Health Sciences Booth, Alison; University of York, UK, Department of Health Sciences Morgan, Sara; University of Southampton Walker, Inna; University of Southampton Chapman, Caroline; Hampshire Constabulary Barlow-Pay, Megan; University of Southampton Cochrane, Ann; University of York, Department of Health Sciences Filby, Emma; University of York, Department of Health Sciences Fleming, Jenny; University of Southampton Highfield Campus, Department of Sociology Hewitt, Catherine; The University of York, Health Sciences Raftery, James; Southampton University, WIHRD, School of Medicine Torgerson, David; The University of York Weir, Lana; University of Southampton Parkes, Julie; University of Southampton, Public Health Sciences and Medical Statistics
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Public health
Keywords:	PUBLIC HEALTH, Adolescents < Adolescent, Randomized Controlled Trial

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Examining the effectiveness of the Gateway conditional caution on health and wellbeing of young**  
4 **adults committing low-level offences: a randomised controlled trial**  
5  
6  
7

8 **Authors:** Alex Mitchell<sup>1</sup>, Alison Booth<sup>1</sup>, Sara Morgan<sup>2</sup>, Inna Walker<sup>2</sup>, Caroline Chapman<sup>3</sup>, Megan  
9 Barlow-Pay<sup>2</sup>, Ann Cochrane<sup>1</sup>, Emma Filby<sup>1</sup>, Jenny Fleming<sup>4</sup>, Catherine Hewitt<sup>1</sup>, James Raftery<sup>2</sup>, David  
10 J. Torgerson<sup>1</sup>, Lana Weir<sup>2</sup>, Julie Parkes<sup>2</sup>  
11  
12  
13

- 14  
15  
16 1. York Trials Unit, Department of Health Sciences, Faculty of Sciences, University of York, York,  
17 UK  
18  
19 2. School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine,  
20 University of Southampton, Southampton, UK  
21  
22 3. Southampton Central Police Station, Hampshire Constabulary, Southampton, UK  
23  
24 4. Department of Sociology, Social Policy and Criminology, Faculty of Social Sciences, University  
25 of Southampton Highfield Campus, Southampton, UK  
26  
27  
28  
29  
30  
31

32 **Corresponding author:** Alex Mitchell, York Trials Unit, Department of Health Sciences, University of  
33 York, York, UK; [alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Background:** Young adults who commit low-level offences commonly have a range of health and social needs and are significantly over-represented in the criminal justice system. These young adults may need to attend court and potentially receive penalties including imprisonment. Alternative routes exist, which can help address the underlying causes of offending. Some feel more should be done to help young adults entering the criminal justice system. The Gateway programme was a type of out-of-court disposal (OCD) developed by Hampshire Constabulary, which aimed to address the complex needs of young adults who commit low-level crimes. This study aimed to evaluate the effectiveness and cost-effectiveness of the Gateway programme, issued as a conditional caution, compared to usual process.

**Methods:** The Gateway study was a pragmatic, parallel-group, superiority randomised controlled trial (RCT) that recruited young adults who had committed a low-level offence from four sites covering Hampshire and Isle of Wight. The primary outcome was mental health and wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcomes were quality of life, alcohol and drug use, and recidivism. Outcomes were measured at 4, 16 and 52 weeks post-randomisation.

**Results:** Due to issues with retention of participants and low data collection rates, recruitment ended early, with 191 eligible participants randomised (Gateway 109; usual process 82). The primary outcome was obtained for 93 (48.7%) participants at 4 weeks, 93 (48.7%) at 16 weeks and 43 (22.5%) at 1 year. The high attrition rates meant that effectiveness could not be assessed as planned.

**Conclusions:** Gateway is the first trial in a UK police setting to have a health-related primary outcome requiring individual data collection, rather than focusing solely on recidivism. We demonstrated that it is possible to recruit and randomise from the study population, however follow-up rates were low. Further work is needed to identify ways to facilitate engagement between researchers and vulnerable populations to collect data.

1  
2  
3 **Trial registration:** ISRCTN11888938  
4  
5

6 **Keywords:** young adults; criminal justice; recidivism; police; vulnerable populations  
7  
8

9 **Word count:** 4568  
10  
11

### 12 **Strengths and limitations of this study**

13  
14

- 15 • The planned pragmatic trial was robustly and transparently planned and involved  
16 close collaboration between a wide range of stakeholders.
- 17 • We were not able to assess effectiveness of the Gateway intervention due to low  
18 data collection rates.
- 19 • Our work on this trial has provided a robust benchmark for attrition which will help  
20 guide future health related trials in the police setting and with 18-24-year old's  
21 committing low level crimes.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 46 **Background**

49 Young adults who commit low-level offences commonly have a range of health and social needs,  
50 making them vulnerable to mental health problems. (1-3) These young offenders are more likely to  
51 come into contact with the police both as suspects and victims of crime and are significantly over-  
52 represented in the criminal justice system, accounting for approximately one third of police,  
53 probation and prison caseloads. (4) According to statistics from Hampshire Constabulary (HC) for

1  
2  
3 2018/20, the five main low-level offence categories for adults aged between 18 and 24 where formal  
4 action was taken by the police are possession of drugs, violence, shoplifting, criminal damage and  
5 public order offences. Young adults who have been investigated for a suspected low-level offence,  
6  
7 may need to attend court and, if convicted, face penalties such as prison.  
8  
9

10  
11  
12 More could be done to help young adults entering the criminal justice system, for example via court  
13 diversion programmes. Diversion is a process whereby an accused person is formally moved into a  
14 programme in the community, such as an out-of-court community-based intervention (OCBI),  
15 instead of a court summons. (5) In the UK, a number of police forces are exploring the use of out-of-  
16 court disposals (an alternative to a court summons) amongst 18–24-year-olds involved in less serious  
17 offending. (6-9) The aim is to divert the young adult away from their offending behaviour through a  
18 rehabilitative path. (10)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 The Gateway programme was issued as a novel form of conditional caution, where release from  
30 custody comes with mutually agreed conditions. Gateway was conceived by HC as a culture-  
31 changing initiative that sought to address the complex needs of adults aged 18-24 years who commit  
32 low-level crimes. However, HC recognised the need for evidence on the effectiveness of Gateway  
33 and were keen on an evaluation of its effectiveness in relation to a wider set of outcomes beyond  
34 recidivism, with a particular focus on health and wellbeing of young people.  
35  
36  
37  
38  
39  
40  
41  
42

43 The aim of this study was therefore to evaluate the effectiveness and cost-effectiveness of the  
44 Gateway programme issued as a conditional caution, compared to usual process (a court  
45 appearance or a different conditional caution), in relation to health and wellbeing of its clients.  
46  
47  
48  
49

## 50 **Methods**

51  
52  
53 A summary of the study methods is given here; full details are available in the published protocol  
54 paper (11), and the protocol available at <https://www.fundingawards.nihr.ac.uk/award/16/122/20>.  
55  
56  
57

## 58 **Study design**

1  
2  
3 The Gateway study was a pragmatic, multicentre, superiority randomised controlled trial (RCT) that  
4 compared two groups of young adults who had committed a low-level offence. Participants were  
5 randomised to either the Gateway conditional caution (intervention) or disposal as usual to a court  
6 summons or a different conditional caution (usual process). An economic evaluation was planned. A  
7 qualitative evaluation of the impact of the intervention on participants and other stakeholders will  
8 be reported elsewhere.  
9  
10  
11  
12  
13  
14  
15  
16

17 Participants were recruited from four sites (Southampton, Portsmouth, Isle of Wight and  
18 Basingstoke Police Stations), covering the whole of Hampshire and Isle of Wight. Follow-up was  
19 carried out at 4-weeks, 16-weeks and 1-year post-randomisation.  
20  
21  
22  
23  
24

### 25 **Participants**

26  
27 Participants were eligible if they were aged 18-24 years, resided in the Hampshire and Isle of Wight  
28 area, were anticipated to give a guilty plea and there was sufficient evidence to provide a realistic  
29 prospect of conviction, and it was in the public interest to prosecute or offer a conditional caution to  
30 the suspect. Exclusion criteria included serious and indictable only offences, and those involving  
31 domestic or sexual violence, knives, hate, serious injury, drink-driving, breach of offence orders and  
32 any serious previous conviction. Those needing an interpreter or having a previous Gateway caution  
33 were excluded.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Recruitment**

45  
46 By law the police must know the destination for an offender at the time of disposal, that is, when  
47 the outcome of the investigation is administered. As the intervention was one of the disposal  
48 options, randomisation had to take place at the time of disposal. HC investigators were trained to  
49 identify, recruit and randomise participants, an approach that had previously been used (12).  
50  
51  
52  
53  
54

55  
56 It was not felt appropriate for police investigators to obtain full consent because of the potential risk  
57 of coercion, nor was it practical, given the timelines. We therefore developed a two-stage consent  
58  
59  
60

1  
2  
3 procedure. During processing in custody, investigators identified potentially eligible participants and  
4  
5 discussed with them the Gateway caution. For legal reasons, the Gateway caution was initially  
6  
7 offered as a disposal option independently of the study. If interest was shown, the young person was  
8  
9 then informed about the study. A Gateway Caution information leaflet (produced by HC  
10  
11 independently of the study) and a study leaflet with a link to an explanatory video were shared.  
12  
13  
14 Potential participants were made aware that further details about the study would be provided by a  
15  
16 researcher and that they could withdraw from the study at any time without giving a reason. If the  
17  
18 young person was interested in the opportunity to receive Gateway and take part in the study, the  
19  
20 investigator obtained stage 1 consent. This allowed HC to share their contact details with the  
21  
22 University of Southampton (UoS) researchers and gave York Trials Unit (YTU) researchers access to  
23  
24 their police record for demographics such as age, gender and ethnicity and offending history, trigger  
25  
26 offence and any subsequent reoffending. This process precluded the collection of baseline outcome  
27  
28 data.  
29  
30

31  
32  
33 Some participants were out of custody when it was decided the arrest criteria had been met and/or  
34  
35 Gateway was suitable. For these participants, verbal consent was obtained over the telephone and  
36  
37 randomisation undertaken at that time. It was therefore possible that the subsequent in person  
38  
39 disposal for some of these participants could occur several weeks after randomisation depending on  
40  
41 when the in-person disposal could be arranged. Study procedures continued as per protocol.  
42  
43

44  
45 Ahead of the week 4 data collection time point, the researchers attempted to contact participants by  
46  
47 telephone, text, email and/or post to arrange an interview. Once arranged, the Stage 2 participant  
48  
49 information sheet was emailed or posted to the participant. At the interview the researcher went  
50  
51 through the information sheet providing explanations as required. If the patient consented, data  
52  
53 collection could occur at the same interview or on a subsequent day. To maximise data collection, if  
54  
55 a participant took part in the week 16 interview having not taken part at week 4, verbal consent was  
56  
57 obtained at that point.  
58  
59  
60



### ***Randomisation and blinding***

Police officers and investigators (hereafter referred to as investigators) coming into contact with potential participants were offered opportunities to undergo related training prior to the start of the study, as well as once the study was live, which was aimed mainly at new staff and as refresher training. Potential participants were screened using an online eligibility tool hosted by Alchemer and developed by HC in discussion with YTU. Eligible young people were consented by investigators using a guidance script developed jointly by HC and the research team. Consenting participants were randomised using a 1:1 allocation ratio with simple randomisation. Researchers involved in consenting and collecting data from participants were blind to allocation. It was not possible to blind participants due to the nature of the intervention.

### ***Intervention and usual care***

The Gateway conditional caution was a police-led intervention delivered using a multi-agency approach.

The Gateway intervention consisted of three compulsory parts.

1. Within 3-5 working days of their disposal, the participant met with a Gateway navigator for a needs assessment. The navigator then assisted the young adult into the appropriate services, including Gateway partner agencies (e.g. housing, alcohol, drug and mental health services). The navigators also undertook midway and final assessments and provided mentoring throughout the programme. The Gateway navigators were trained support workers, provided by a third sector organisation, No Limits, and by Southampton City Council.
2. Attendance at two LINX workshops run by The Hampton Trust aimed to assist young adults in the development of cognitive and affective empathy and prevent reoffending. These were delivered between weeks 2-3 and 5-6 post randomisation.

3. Undertaking not to reoffend during the 16 weeks of the conditional caution.

Additional conditions could also be added at the discretion of the supervising officer approving the disposal destination. If a participant reoffended during the period of their caution, the HC Gateway Team could use their discretion when deciding whether a breach had occurred. If a participant was considered to have breached the terms of the caution, they were withdrawn from the Gateway intervention, and the original investigator considered whether to prosecute the participant for the original offence. Participants who breached their Gateway Conditional Caution continued to be approached for data collection.

Participation in Restorative Justice could be requested by the victim, but this was not part of the standard Gateway caution.

Usual process consisted of either a different conditional caution or the participant being charged to appear in court. Examples of conditions attached to the usual process caution include apology letters, victim awareness courses, drug or alcohol diversion courses, fines and compensation.

### **Changes to the intervention and usual process as a result of the COVID-19 pandemic**

In response to government restrictions, on 22 March 2020 HC halted all conditional caution activities that involved face-to-face interaction. The in-person nature of the Gateway intervention meant delivery modes had to change. The Navigators modified their practice to undertake needs assessments and meetings with clients by telephone as standard. The content and purpose of the initial needs assessment and subsequent contact remained the same. The Hampton Trust modified the workshops to be delivered one-to-one over the telephone. The principles and key elements of the workshops were maintained but reduced in length from 10 hours to two hours. Face-to-face working returned in May 2021, where appropriate and risk assessed.

In terms of usual care, simple cautions and conditional cautions with conditions relating to fines, compensation and apology letters continued to be issued; court proceedings were halted. However,

1  
2  
3 as the intervention was unavailable, recruitment was halted on 23<sup>rd</sup> March 2020. In August 2020, HC  
4  
5 restarted all conditional cautions, including Gateway.  
6  
7

## 8 **Outcomes**

9  
10 The primary outcome was the Warwick-Edinburgh Wellbeing Scale (WEMWBS), which measures  
11  
12 mental health and wellbeing. The WEMWBS consists of 14 items, each with a 5-point scale. The total  
13  
14 score ranges from 14-70, with a higher score indicating a higher level of health and wellbeing.  
15  
16

17  
18 The patient-reported secondary outcomes were the Short Form-12 (SF-12) mental and physical  
19  
20 components, Alcohol Use Disorders Identification Test (AUDIT) and Adolescent Drug Involvement  
21  
22 Scale (ADIS) scores. The ADIS also has an additional section on the use of different types of drugs  
23  
24 that enables a score titled the Index of Multiple Drug Use to be scored. This was not a study  
25  
26 outcome but is reported in the results. Secondary outcomes measuring recidivism one-year post-  
27  
28 randomisation were the total number of police records management system (RMS) incidents, the  
29  
30 total number of RMS incidents resulting in being charged or cautioned, the total number of police  
31  
32 national computer (PNC) convictions, whether the participant was charged with a summary or  
33  
34 either-way offence and whether the participant was charged with an indictable only offence. In the  
35  
36 statistical analysis plan it was originally stated the first two recidivism outcomes would be the total  
37  
38 number of RMS incidents plus the total number of PNC convictions up to one-year post-  
39  
40 randomisation and the total number of RMS incidents resulting in being charged or cautioned plus  
41  
42 the total number of PNC convictions. However, on receipt of the RMS and PNC data we found that a  
43  
44 single offence could be classed as both an incident in the RMS data and a conviction in the PNC data,  
45  
46 and hence would lead to double counting when deriving these two recidivism outcomes. It was  
47  
48 therefore decided to separate out the number of PNC convictions and report it as its own outcome.  
49  
50  
51  
52  
53

## 54 ***Patient and public involvement***

55  
56  
57  
58  
59  
60

1  
2  
3 PPI was embedded early on with the help of partners The Hampton Trust (HT). Meetings with young  
4 adults on an HT programme explored various aspects of the study, including importance,  
5 acceptability and feasibility. The groups fed back in detail around the logistics of the study: the  
6 process around consent and randomisation; ways to manage challenges following up the control  
7 arm; and opinion on assessment forms.  
8  
9  
10  
11  
12  
13  
14

15 Once the study was underway, the PPI lead worked with partners to involve young adult  
16 representatives who had been through the Gateway programme and those who had been through  
17 the 'usual process'. Consultation and input from these service users provided a clear understanding  
18 of the challenges and benefits that participants with and without prior experience of the criminal  
19 justice system might face. These PPI representatives worked closely with the PPI lead to develop  
20 consent forms, PISs, and initial information leaflets, plan recruitment strategies and consider the  
21 most effective ways of arranging interviews and qualitative work.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 There were two public representatives on the Study Steering Committee/Data Monitoring and Ethics  
32 Committee (SSC/DMEC). An ex-offender, working for Hampshire Youth Offenders Team (HYOT) as a  
33 peer mentor and support worker; and a victim advocate, working for a charity for victims of crime.  
34 They represented the voice of the service users and victims at Steering Group meetings, helping the  
35 group reflect on the realities of delivering the programme from the user perspective, reminding the  
36 group of some of the vulnerabilities and needs of this population, and ensuring the views of victims  
37 were considered.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 These two representatives also worked closely with the study PPI lead, providing strategic input,  
49 advice and guidance throughout, with a particular focus on the logistics of getting the project  
50 underway, reviewing and adapting the protocol. The idea of a recruitment video was conceived by  
51 the ex-offender public representative, and the content was co-created with them.  
52  
53  
54  
55  
56

57 Utilising links established through a local outreach programme, community leaders and members of  
58 the public were consulted. We worked closely with these individuals to ensure we understood the  
59  
60

1  
2  
3 concerns and attitudes of the wider community. Additionally, they were able to provide input to  
4  
5 public facing documentation and materials.  
6  
7

### 8 ***Statistical analysis*** 9

10  
11 It has been suggested that a change of three or more points on the WEMWBS is likely to be  
12  
13 important to individuals, although different statistical approaches provide different estimates  
14  
15 ranging from three to eight points (WEMWBS user guide(13)). Estimates of the standard deviation  
16  
17 also vary between 6 and 10.8(14), with a pooled estimate of 10 across all studies. Assuming 90%  
18  
19 power, 5% statistical significance, a minimal clinically important difference of 5 points on the  
20  
21 WEMWBS and a standard deviation of 10, 266 participants were required. Preliminary figures from  
22  
23 The Hampton Trust's Raising Awareness of Domestic Abuse in Relationships (RADAR) intervention  
24  
25 suggested a drop-out rate of approximately 15%. Assuming a conservative 20% attrition rate, we  
26  
27 aimed to recruit and randomise 334 participants.  
28  
29

30  
31  
32 Analyses were conducted in Stata® version 17 (StataCorp LP; College Station, TX, USA) and followed  
33  
34 a pre-specified statistical analysis plan (SAP) approved by the Study Steering and Data Monitoring  
35  
36 and Ethics Committee prior to the completion of data collection.  
37  
38

39  
40 Version 1.0 of the SAP outlined the planned analyses to assess the effectiveness of the Gateway  
41  
42 intervention, however poor retention and data collection rates made this unfeasible. Version 1.1 of  
43  
44 the SAP removed all reference to formal hypothesis testing and outlined purely descriptive analyses.  
45  
46

47  
48 Continuous measures were summarised using counts, mean, standard deviation, median,  
49  
50 interquartile range (IQR), minimum and maximum. Categorical measures were summarised using  
51  
52 counts and percentages. All participants were analysed according to their randomised group, unless  
53  
54 otherwise stated. The flow of participants from eligibility and randomisation to follow-up and  
55  
56 analysis of the trial was presented in a Consolidated Standards of Reporting Trials (CONSORT) flow  
57  
58 diagram.(15) Reasons for ineligibility and non-consent were given. The number of withdrawals and  
59  
60

1  
2  
3 reasons for withdrawal at each time point were summarised descriptively by randomised treatment  
4 group. Participant demographics were summarised descriptively by randomised treatment group,  
5  
6 both for all participants randomised and participants who provided the primary outcome data for at  
7  
8 least one timepoint. No formal statistical comparisons were undertaken between groups.  
9

10  
11  
12 For those who received Gateway, the number of LINX workshops attended, delivery of LINX  
13  
14 workshops, contacts attempted by the navigator, successful contacts made by the navigator and  
15  
16 total duration of successful contacts were summarised descriptively. For participants who were  
17  
18 cautioned, the conditions attached to each caution were summarised descriptively by whether the  
19  
20 participant received the Gateway conditional caution or a different caution.  
21  
22

23  
24 The primary, secondary and exploratory outcomes were summarised descriptively at each timepoint  
25  
26 by randomised group.  
27

28  
29 Intervention compliance was defined as both minimal compliance and full compliance. Minimal  
30  
31 compliance was met when the participants engaged with their navigator at the initial, midway and  
32  
33 final assessments, attended the two LINX workshops and had not been breached for reoffending  
34  
35 during the duration of the conditional caution. Full compliance was met when the conditions for  
36  
37 minimal compliance were met, and in addition the participant engaged with external agencies  
38  
39 organised by the navigator.  
40  
41

42  
43 The number and proportion of participants informed of their disposal decision after their 4-week  
44  
45 follow-up was due, was presented by randomised treatment group. The number of days between  
46  
47 randomisation and date of disposal were summarised descriptively, alongside whether the  
48  
49 participant attended their 4-week follow-up. The number and proportion of participants in the  
50  
51 intervention group who violated the condition to reoffend was presented. For these participants, the  
52  
53 number for whom discretion was considered before taking the decision to breach was reported.  
54  
55  
56

## 57 58 **Results** 59 60

1  
2  
3 Due to issues with retention of participants and data collection rates, recruitment ended on 13<sup>th</sup>  
4  
5 December 2021, and data was collected for participants due up until 31<sup>st</sup> March 2022.  
6  
7

8  
9 Between the 1<sup>st</sup> of October 2019 and 13<sup>th</sup> December 2021 345 potentially eligible young people were  
10 screened, of which 298 (86.4%) were eligible. Of the 298 eligible, 106 (35.6%) did not consent to the  
11 study. Of these, 77 (72.6%) refused the study but accepted the Gateway caution; 5 (4.7%) refused  
12 the Gateway caution; 2 (1.9%) ran out of prosecution time; and 2 (1.9%) were missed by the  
13 recruiting investigator (reason unknown). There were 20 (18.9%) for whom the reason for non-  
14 consent is unknown. In total, 192 (64.4%) participants were recruited and randomised. One  
15 participant was randomised in error, which led the custody sergeant to non-randomly assign the  
16 participant. This participant is excluded from all further analyses, meaning 191 participants were  
17 randomised and included in the analyses (Gateway 109; usual process 82; Figure 1).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 **INSERT FIGURE ONE HERE**

30 The mean age of participants was 20.8 years (range 18.1-24.8) and 144 (78.7%) were male (Table 1).  
31  
32 The median total number of RMS incidents involved in 1-year pre-randomisation was 6 (3, 13), with  
33 57 (31.5%) participants involved in an RMS incident that led to a caution or charge during this  
34 period. Baseline characteristics of the randomised participants were generally balanced between  
35 groups, except for small imbalances in gender and highest level of education. For participants who  
36 provided a valid WEMWBS score, there was an imbalance in the proportion of participants  
37 previously convicted that was larger than the imbalance observed in all randomised participants.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Participant characteristics presented by allocated group, for all randomised participants and all randomised participants who provided a valid WEMWBS score for at least one timepoint.

	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
<b>Age at randomisation</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Mean (SD)	20.8 (2.0)	20.7 (1.9)	20.8 (1.9)	20.7 (2.0)	20.7 (1.7)	20.7 (1.9)
Median (IQR)	20.3 (19.3, 22.5)	20.4 (19.3, 21.6)	20.4 (19.3, 22.0)	20.2 (19.0, 22.3)	20.5 (19.4, 21.4)	20.3 (19.3, 21.6)
Min, Max	18.1, 24.8	18.1, 24.8	18.1, 24.8	18.1, 24.7	18.1, 24.7	18.1, 24.7
<b>Gender, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>78 (95.1)</b>	<b>183 (95.8)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Male	87 (82.9)	57 (73.1)	144 (78.7)	51 (79.7)	32 (72.7)	83 (76.9)
Female	18 (17.1)	21 (26.9)	39 (21.3)	13 (20.3)	12 (27.3)	25 (23.1)
<b>Marital status, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
Single	62 (93.9)	38 (86.4)	100 (90.9)	60 (93.8)	38 (86.4)	98 (90.7)
Living with partner	4 (6.1)	5 (11.4)	9 (8.2)	4 (6.2)	5 (11.4)	9 (8.3)
Married	0 (0)	1 (2.3)	1 (0.9)	0 (0)	1 (2.3)	1 (0.9)
<b>Ethnicity, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>182 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>108 (100)</b>
White North European	96 (91.4)	75 (96.2)	170 (93.4)	58 (90.6)	44 (100)	102 (94.4)
Black	5 (4.8)	2 (2.6)	7 (3.8)	3 (4.7)	0 (0)	3 (2.8)
Asian	2 (1.9)	1 (1.3)	3 (1.6)	1 (1.6)	0 (0)	1 (0.9)
White South European	1 (1.0)	0 (0)	1 (0.5)	1 (1.6)	0 (0)	1 (0.9)
<b>Highest level of education, n (%)</b>						
<b>Number with data, n (%)</b>	<b>66 (60.6)</b>	<b>44 (53.7)</b>	<b>110 (57.6)</b>	<b>64 (100)</b>	<b>44 (100)</b>	<b>108 (100)</b>
No qualifications	14 (21.2)	3 (6.8)	17 (15.5)	14 (21.9)	3 (6.8)	17 (15.7)
1-4 GCSEs	20 (30.3)	8 (18.2)	28 (25.5)	20 (31.3)	8 (18.2)	28 (25.9)
More than 5 GCSEs	13 (19.7)	11 (25.0)	24 (21.8)	13 (20.3)	11 (25.0)	24 (22.2)
Apprenticeship	2 (3.0)	5 (11.4)	7 (6.4)	2 (3.1)	5 (11.4)	7 (7.5)
2 or more A-levels	17 (25.8)	15 (34.1)	32 (29.1)	15 (23.4)	15 (34.1)	30 (27.8)
Bachelor's degree or higher	0 (0)	2 (4.5)	2 (1.8)	0 (0)	2 (4.5)	2 (1.9)
<b>IMD quintile (1=most deprived, 5=least deprived), n (%)</b>						
<b>Number with data, n (%)</b>	<b>94 (86.2)</b>	<b>72 (87.8)</b>	<b>166 (86.9)</b>	<b>58 (90.6)</b>	<b>42 (95.5)</b>	<b>100 (92.6)</b>
1	21 (22.3)	20 (27.8)	41 (24.7)	14 (24.1)	14 (33.3)	28 (28.0)
2	25 (26.6)	17 (23.6)	42 (25.3)	14 (24.1)	9 (21.4)	23 (23.0)
3	15 (16.0)	14 (19.4)	29 (17.5)	9 (15.5)	8 (19.0)	17 (17.0)
4	16 (17.0)	7 (9.7)	23 (13.9)	9 (15.5)	4 (9.5)	13 (13.0)
5	17 (18.1)	14 (19.4)	31 (18.7)	12 (20.7)	7 (16.7)	19 (19.0)
<b>Entry route, n (%)</b>						
<b>Number with data, n (%)</b>	<b>105 (96.3)</b>	<b>77 (93.9)</b>	<b>182 (95.3)</b>	<b>64 (100)</b>	<b>43 (97.8)</b>	<b>107 (99.1)</b>
Caution	93 (88.6)	72 (93.5)	165 (90.7)	57 (89.1)	42 (97.7)	99 (92.5)
Prosecution	12 (11.4)	5 (6.5)	17 (9.3)	7 (10.9)	1 (2.3)	8 (7.5)
<b>Total number of RMS incidents involved in 1-year pre-randomisation (not including RMS incident that led to study entry)</b>						



	Randomised participants (n=191)			Provided valid WEMWBS for at least one timepoint (n=108)		
	Gateway conditional caution (n=109)	Usual process (n=82)	Total (n=191)	Gateway conditional caution (n=64)	Usual process (n=44)	Total (n=108)
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	10.8 (12.5)	12.9 (25.7)	11.7 (19.2)	9.3 (8.7)	9.0 (9.9)	9.2 (9.2)
Median (IQR)	7 (3, 13)	6 (3, 12)	6 (3, 13)	6 (3, 13)	5 (3, 12)	6 (3, 13)
Min, Max	0, 79	1, 200	0, 200	0, 35	1, 38	0, 38
<b>Total number of RMS incidents leading to charge or caution 1-year pre-randomisation (not including charge or caution that led to study entry)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.6 (1.0)	0.5 (1.3)	0.5 (1.1)	0.6 (1.0)	0.3 (0.6)	0.5 (0.9)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0.5)	0 (0, 1)
Min, Max	0, 4	0, 10	0, 10	0, 4	0, 2	0, 4
<b>Total number of PNC convictions 1-year pre-randomisation</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Mean (SD)	0.5 (0.8)	0.3 (0.5)	0.4 (0.7)	0.4 (0.7)	0.2 (0.5)	0.3 (0.6)
Median (IQR)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 2	0, 3	0, 2	0, 2	0, 2
<b>Involved in RMS incident that led to caution or charge 1-year pre-randomisation (not including charge or caution that led to study entry), n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	36 (34.6)	21 (27.3)	57 (31.5)	21 (33.3)	11 (25.0)	32 (29.9)
No	68 (65.4)	56 (72.7)	124 (68.5)	42 (66.7)	33 (75.0)	75 (70.1)
<b>PNC conviction 1-year pre-randomisation, n (%)</b>						
<b>Number with data, n (%)</b>	<b>104 (95.4)</b>	<b>77 (93.9)</b>	<b>181 (94.8)</b>	<b>63 (98.4)</b>	<b>44 (100)</b>	<b>107 (99.1)</b>
Yes	31 (29.8)	22 (28.6)	53 (29.3)	16 (25.4)	8 (18.2)	24 (22.4)
No	73 (70.2)	55 (71.4)	128 (70.7)	47 (74.6)	36 (81.8)	83 (77.6)
N = number; Min = minimum; Max = maximum; SD = standard deviation; RMS = record management system; PNC = police national computer						

Of the 109 participants randomly assigned Gateway, 104 (95.4%) received Gateway with four of the remaining five receiving a standard caution. Of the 81 (98.8%) participants who were randomly assigned to and received usual process, 76 (93.8%) entered the study via the caution route i.e. received a different conditional caution. There were 18 (17.1%) who received a Gateway caution with the additional condition of providing compensation, while 5 (4.8%) were required to write a letter of apology the victim. Of those who received a simple or conditional caution, the most

1  
2  
3 common conditions attached were compensation (n=20; 25.0%), attending a drug diversion course  
4  
5 (n=16; 20.0%) and attending a victim awareness course (n=14; 17.5%).  
6  
7

8 Of the 105 participants who received Gateway, data on number of LINX sessions attend was received  
9  
10 for 101 (96.2%), of which 88 (87.1%) attended both sessions, 1 (1.0%) attended one session, 8 (7.9%)  
11  
12 did not attend any sessions, while 4 (4.0%) could not attend due to the COVID-19 pause. Of those  
13  
14 who attended at least one workshop, 45 (56.3%) attended a face-to-face workshop while 35 (43.8%)  
15  
16 had the workshop delivered via the telephone. The median number of successful contacts made by  
17  
18 the navigator to the participant was 19 (IQR 15 to 31). For each participant the total duration of  
19  
20 successful contacts was calculated, the median of which was 626.5 minutes (IQR 380, 978). Further  
21  
22 information on the delivery of Gateway and usual process is presented in Appendix A in the  
23  
24 supplementary materials.  
25  
26  
27  
28

29 At the primary endpoint of one-year post-randomisation, 43 (22.5%) case report forms (CRFs) were  
30  
31 returned (Gateway 27,24.8%; usual process 16,19.5%) (Figure 1). At 4-weeks post-randomisation 94  
32  
33 (49.2%) CRFs were returned (Gateway 58, 53.2%; usual process 36, 43.9%) while at 16 weeks post-  
34  
35 randomisation 95 (49.7%) (Gateway 56, 51.4%; usual process 39,47.6%). The WEMWBS, SF-12,  
36  
37 AUDIT and ADIS data for one participant in the Gateway group was excluded at week 4 due to the  
38  
39 questionnaire being completed too early. At week 16 the data for two participants in the Gateway  
40  
41 group were excluded due to the questionnaires being completed too late.  
42  
43  
44

45 Valid participant-reported outcome data was provided by 96 (50.3%) participants at the 4-week  
46  
47 follow-up, 93 (48.7%) participants at the 16-week follow-up and 43 (22.5%) participants at the 1-year  
48  
49 follow-up (Gateway 56, 51.4%; usual process 39, 47.6%. Descriptive summaries of the primary and  
50  
51 secondary outcomes are provided in Table 2 and Table 3 respectively.  
52  
53  
54

55 There were 129 (67.5%) participants who had reached the one-year follow-up before their RMS data  
56  
57 was extracted by HC on the 23<sup>rd</sup> of June 2022, while 125 (65.4%) reached the one-year follow-up  
58  
59 before their PNC data was extracted. Ten participants who withdrew before or after stage 2 consent,  
60

declined stage 2 consent or lost mental capacity did not have their RMS and PNC data reported. Of the 32 participants in the Gateway group who had been in the study less than one year, 2 (6.3%) had been charged with a summary or either-way offence, while of the 24 participants in the usual process group, 2 (8.3%) had been charged. For the 56 participants who had been in the study less than one year, the mean time between date of randomisation and date of data extraction was 286.9 days (SD 56.7 days). Table 4 gives descriptive summaries of the recidivism outcomes.

**Table 2:** The WEMWBS score at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	44.1 (9.6)	44.9 (7.2)
Median (IQR)	45 (38, 52)	44 (41, 49)
Min, Max	19, 61	28, 62
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	48.6 (9.9)	46.0 (8.5)
Median (IQR)	49 (42, 55)	47 (40, 53)
Min, Max	27, 67	30, 60
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.4 (9.7)	45.7 (7.0)
Median (IQR)	49 (41, 54)	45.5 (41.5, 50.5)
Min, Max	29, 68	28, 58

**Table 3:** Secondary and exploratory participant-reported outcomes at each timepoint, presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>SF-12 Mental Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	42.4 (12.0)	43.5 (9.7)
Median (IQR)	43.6 (35.7, 53.1)	43.8 (36.8, 51.9)
Min, Max	15.1, 58.8	22.1, 58.8
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	47.7 (7.6)	45.0 (9.1)
Median (IQR)	47.7 (41.7, 54.6)	45.8 (38.7, 52.7)
Min, Max	34.3, 58.8	20.7, 58.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	47.5 (7.5)	46.1 (8.6)
Median (IQR)	47.7 (39.5, 54.6)	47.5 (44.4, 51.8)
Min, Max	34.3, 58.8	20.7, 58.1
<b>SF-12 Physical Component</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	54.5 (5.3)	52.8 (6.7)
Median (IQR)	55.5 (53.7, 57.4)	55.2 (51.2, 56.8)
Min, Max	36.8, 63.9	30.8, 59.2
<b>Week 16</b>		

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	52.5 (6.4)	53.4 (5.7)
Median (IQR)	54.5 (51.7, 56.0)	55.2 (52.4, 56.9)
Min, Max	26.1, 59.4	38.0, 60.1
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	51.9 (7.9)	53.5 (6.3)
Median (IQR)	54.5 (51.7, 56.5)	55.3 (52.5, 58.2)
Min, Max	26.1, 59.4	38.0, 58.9
<b>AUDIT</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	12.9 (9.2)	11.2 (7.5)
Median (IQR)	11 (5, 19)	10.5 (5.5, 16.5)
Min, Max	0, 34	0, 28
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	11.6 (8.1)	11.6 (8.7)
Median (IQR)	9.5 (5, 15)	10 (4, 16)
Min, Max	0, 32	0, 36
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	11.1 (8.5)	13.3 (8.3)
Median (IQR)	8 (5, 20)	12.5 (8, 17)
Min, Max	0, 30	1, 30
<b>ADIS</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	46.9 (33.6)	45.1 (36.5)
Median (IQR)	38 (25, 59)	37.5 (12, 76.5)
Min, Max	0, 137	0, 111
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	40.9 (36.3)	37.2 (38.2)
Median (IQR)	36.5 (15, 52)	31 (0, 67)
Min, Max	0, 137	0, 111
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	48.7 (36.1)	50.5 (39.0)
Median (IQR)	40 (23, 68)	38.5 (20.5, 86)
Min, Max	0, 134	0, 111
<b>Accommodation status (exploratory), n (%)</b>		
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Homeless	8 (14.0)	3 (8.3)
Not homeless	49 (86.0)	33 (91.7)
<b>Year 1, n (%)</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Homeless	3 (11.1)	0 (0)
Not homeless	24 (88.9)	15 (100)

**Table 4:** Recidivism outcomes presented by allocated group.

	Gateway conditional caution (n=109)	Usual process (n=82)
<b>RMS incidents involved in up to one-year post-randomisation</b>		
Number with data, n (%)	74 (67.9)	55 (67.1)
Mean (SD)	9.3 (12.2)	12.2 (23.7)
Median (IQR)	5 (1, 14)	5 (1, 11)
Min, Max	0, 61	0, 132
<b>Total number of RMS incidents resulting in being classed as a suspect and charged/cautioned up to one-year post-randomisation</b>		
Number with data, n (%)	74 (67.9)	55 (67.1)
Mean (SD)	0.4 (1.2)	0.8 (2.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 7	0, 20
<b>Total number of PNC convictions up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (64.6)
Mean (SD)	0.4 (0.8)	0.4 (0.9)
Median (IQR)	0 (0, 0)	0 (0, 0)
Min, Max	0, 3	0, 5
<b>Charged with a 'summary' or 'either way' offence up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (63.9)
Charged	19 (26.4)	16 (30.2)
Not charged	53 (73.6)	37 (69.8)
<b>Charged with an 'indictable only' offence up to one-year post-randomisation</b>		
Number with data, n (%)	72 (66.1)	53 (64.6)
Charged	0 (0)	0 (0)
Not charged	72 (100)	53 (100)

Of the 105 participants randomly allocated to the Gateway conditional caution who did not withdraw before stage 2 or withdraw stage 2 consent, 81 (77.1%) met the definition for minimal compliance. Thirteen participants did not meet minimal compliance due to not attending the two LINX sessions, six did not meet minimal compliance due to breaching the condition to not reoffending during the period of the caution and five were given usual process despite being randomly assigned to the Gateway conditional caution.

No participants were withdrawn from the Gateway conditional caution because they failed to engage with referral agencies identified by the navigator, therefore the number of participants meeting full compliance was 81 (77.1%).

1  
2  
3 Of the 191 randomised participants, 15 (7.9%) were informed of their disposal decision after their 4-  
4 week follow-up was due (Gateway 12, 11.1%; usual process 3, 3.7%; see Appendix B of the  
5 supplementary materials).  
6  
7  
8

9  
10 Of the 105 participants who received the Gateway conditional caution who did not withdraw before  
11 stage 2 or withdraw stage 2 consent, 8 (7.6%) reoffended during the period of the conditional  
12 caution. There were two (25.0%) participants for whom discretion was applied before taking the  
13 decision that they were in breach of the condition not to reoffend. The remaining 6 (75.0%) were  
14 referred back to the original investigator. Due to the risk of data disclosure further information is not  
15 provided here.  
16  
17  
18  
19  
20  
21  
22  
23

24 Information on the Index of Multiple Drug Use, adverse childhood experiences and the health  
25 economic data are presented in appendices C, D and E respectively.  
26  
27  
28  
29

### 30 **Discussion**

31  
32 The Gateway study is the first RCT in the UK police setting to have a health-related primary outcome  
33 requiring consent and individual data collection rather than prioritising criminal justice data on  
34 recidivism. We have demonstrated that is possible, using a novel two-stage consent process, to  
35 recruit and randomise young people who have committed a minor offence to an RCT in the police  
36 setting. Out of court disposals issued by the police such as conditional cautions for less serious  
37 offences have been used in practice for over a decade.<sup>(6)</sup> Evaluations of such interventions have  
38 been carried out, including Cautioning and Relationship Abuse (CARA) (9), Checkpoint (5) and  
39 Operation Turning Point<sup>(9)</sup> to assess their impact on recidivism. Our study differed from these  
40 examples in that our primary outcome was health related. For ethical reasons therefore we needed  
41 participant consent prior to randomisation. A considerable amount of additional work to set up and  
42 for the investigators to administer at a time of stress for potential participants. We were only able to  
43 recruit because of the close collaboration between the research team and Hampshire Constabulary.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 A key limitation of the study is that due to high attrition rates, the study was ended early and an  
7  
8 assessment of the effectiveness of the Gateway intervention compared to usual process could not  
9  
10 be completed. Similar issues with the follow-up and the collection of health data have been found in  
11  
12 other community-based studies in disadvantaged populations, especially those with young people.  
13  
14 (16, 17) We implemented numerous strategies to overcome our issues with retention including a  
15  
16 telephone call reminder about the study from the HC Gateway Project Officer before stage 2 consent  
17  
18 was due. Our public involvement work with vulnerable young people resulted in valuable  
19  
20 suggestions, which we implemented, including changing the wording on participant facing  
21  
22 information and creating a video explaining the study. We also increased the value of the shopping  
23  
24 gift cards on offer for return of outcome data. In addition, we put into place strategies to improve  
25  
26 recruitment, including expansion of the study catchment area and following up the non-screening of  
27  
28 a potentially eligible participant with the recruiting police staff member to ascertain the factors that  
29  
30 led to this. However, we were unable to solve the barrier presented by out-of-date or invalid contact  
31  
32 details, as well as the lack of response by the participants to contact attempts by the researchers.  
33  
34  
35  
36  
37  
38 The groups were generally well balanced in terms of characteristics and percentage providing data,  
39  
40 and allocation did not appear to make any difference to level of engagement. Participants who took  
41  
42 part in data collection interviews completed all parts of the WEMWBS, SF-12, AUDIT and ADIS  
43  
44 instruments at all time points. This suggests that the questions were not overly burdensome or  
45  
46 intrusive and that telephone interviews were acceptable to those willing to share a valid telephone  
47  
48 number.  
49  
50

51  
52 The challenges in recruiting and retaining participants that we faced, and the strategies we put in  
53  
54 place to overcome them will help researchers planning and carrying out future studies with this  
55  
56 population. We have also provided a benchmark for attrition in this population and setting, which  
57  
58  
59  
60

1  
2  
3 indicates that further work is needed to identify ways to facilitate engagement between researchers  
4  
5 and this vulnerable population.  
6  
7

8 A regression discontinuity design (RDD) may be a pragmatic solution to the recruitment issues  
9  
10 encountered by the Gateway trial,(18) that has been used before in the criminal justice setting.(19,  
11  
12 20) The RDD is a quasi-experimental design that allocates participants to intervention or control  
13  
14 according to their score on a continuous baseline variable, with the outcome being a continuous  
15  
16 measure. If there is no effect of the intervention, then the regression plots of the allocation variable  
17  
18 against the outcome of interest will be smooth with no interruption at the point of allocation on the  
19  
20 pre-test variable. However, if the intervention is effective then there will be a change or  
21  
22 discontinuity in the regression slope at the point of allocation.  
23  
24  
25

26  
27 For example, in the criminal justice setting a prospective RDD could use a standardised offender risk  
28  
29 score to assign treatment, with participants scoring above a certain threshold being allocated to the  
30  
31 intervention, which is probably more logical and acceptable to staff and offenders than the use of  
32  
33 randomisation. A prospective design would allow for outcomes that may not be routinely collected,  
34  
35 but are relevant to health care professionals and the police, to be collected as part of the study. In  
36  
37 theory, the RRD would mitigate against selection bias by assuming that measurement error around  
38  
39 the threshold point produces equivalent groups.  
40  
41  
42

### 43 **Conclusion**

44  
45  
46 We have demonstrated that it is possible to recruit and randomise this study population in a police  
47  
48 setting, but recruitment and retention estimates should be conservative. However, more work is  
49  
50 needed to identify strategies to improve retention rates when carrying out research with this  
51  
52 underserved population.  
53  
54

### 55 **List of abbreviations**

ADIS	Adolescent Drug Involvement Scale
AUDIT	Alcohol Use Disorders Identification Test





1  
2  
3 required: HRA Research Ethics Service, Social Care REC approval, Her Majesty Prison Probation  
4  
5 Services.

### 8 ***Availability of data and materials***

10  
11 Data will be made available on reasonable request to the study statistician  
12  
13 ([alex.mitchell@york.ac.uk](mailto:alex.mitchell@york.ac.uk)), who will consult with the chief investigator and trial management group  
14  
15 before a final decision is made.

### 18 ***Competing interests***

20  
21 Catherine Hewitt was Deputy Chair of the NIHR HTA commissioning board, NIHR CTU Standing  
22  
23 Advisory Committee, HTA Post-Funding Committee teleconference and the HTA Funding Committee  
24  
25 Policy Group. James Raftery is a member of the NIHR Editorial Board for HTA and EME. Julie Parkes is  
26  
27 Director of Training, UK Faculty of Public Health. There are no other declared competing interests.  
28  
29

### 32 ***Funding***

34  
35 The Gateway trial was funded by the National Institute of Health Research (NIHR) Public Health  
36  
37 Research Programme (award ID: 16/122/20).  
38

### 40 ***Authors' contributions***

42  
43 **Alex Mitchell**, (<https://orcid.org/0000-0001-9311-2092>) (Statistician, Health Sciences), contributed  
44  
45 to the overall study design, wrote the statistical analysis plan, conducted the statistical analysis,  
46  
47 contributed to writing and editing the manuscript.  
48

49  
50 **Alison Booth**, (<https://orcid.org/0000-0001-7138-6295>) (Senior Research Fellow, Health Sciences)  
51  
52 was a co-investigator, contributed to conceptualisation and design, funding acquisition, protocol  
53  
54 development, and was trial manager for the conduct and delivery of the trial, site setup and data  
55  
56 management, manuscript writing and editing.  
57  
58  
59  
60

1  
2  
3 **Sara Morgan**, (<https://orcid.org/0000-0001-8346-6655>) (Lecturer, Public Health) was a co-  
4 investigator, contributed to conceptualisation and design, funding acquisition, protocol  
5 development, conduct and delivery of the trial and qualitative evaluation, data acquisition,  
6 qualitative analysis and manuscript commenting.  
7  
8  
9

10  
11  
12 **Inna Walker**, (<https://orcid.org/0000-0002-8460-8130>) (Clinical Research Fellow, quantitative and  
13 qualitative researcher) contributed to protocol development and study design, conduct and delivery  
14 of the trial and qualitative evaluation, data acquisition, qualitative analysis, manuscript commenting.  
15  
16  
17

18  
19  
20 **Megan Barlow-Pay**, (<https://orcid.org/0000-0003-1473-2096>) (Patient and Public Involvement and  
21 Engagement (PPIE) and researcher) was the PPI lead for the study, undertook PPI work, contributed  
22 to study design and conduct, quantitative data collection qualitative data collection and analysis, and  
23 commenting on the manuscript.  
24  
25  
26

27  
28  
29 **Caroline Chapman**, (<https://orcid.org/0000-0002-6498-5932>) (Sergeant, Gateway Project Support  
30 Officer for Hampshire Constabulary) contributed to protocol development, trial conduct, setting up  
31 of sites, data acquisition and checking, commented on the manuscript.  
32  
33  
34

35  
36  
37 **Ann Cochrane**, (<https://orcid.org/0000-0002-1502-6719>) (Trial Coordinator, Health Sciences),  
38 contributed to protocol development, trial conduct, setting up of sites, data acquisition and  
39 processing and commented on the manuscript.  
40  
41  
42

43  
44  
45 **Emma Filby**, (<https://orcid.org/0000-0002-1090-1123>) (Data administrator, Health Sciences)  
46 contributed to the study conduct, project administration, data management, and commented on the  
47 manuscript.  
48  
49  
50

51  
52 **Jenny Fleming**, (<https://orcid.org/0000-0002-7913-3345>) (Professor in Criminology, qualitative  
53 methodologist) was a co-investigator contributing to conceptualisation and design, funding  
54 acquisition, protocol development, trial conduct, and commenting on the manuscript.  
55  
56  
57  
58  
59  
60

1  
2  
3 **Catherine Hewitt**, (<https://orcid.org/0000-0002-0415-3536>) (Professor in Statistics, Health Sciences)  
4  
5 was a co-investigator, she contributed to conceptualisation and design, funding acquisition, protocol  
6  
7 development, provided oversight of trial conduct and the statistical analysis, and commented on the  
8  
9 manuscript.  
10

11  
12  
13 **James Raftery**, (<https://orcid.org/0000-0003-1094-8578>) (Professor in Health Economics), as a  
14  
15 coinvestigator, contributed to conceptualisation and design, funding acquisition, protocol  
16  
17 development, trial conduct, and commented on the manuscript.  
18

19  
20 **David Torgerson**, (<https://orcid.org/0000-0002-1667-4275>) (Professor, Director of York Trials Unit)  
21  
22 as a co-investigator, contributed to conceptualisation and design, protocol development, funding  
23  
24 acquisition, trial conduct, and commented on the manuscript.  
25

26  
27  
28 **Lana Weir**, (<https://orcid.org/0000-0003-4730-7969>) (Trial Coordinator, qualitative researcher),  
29  
30 contributed to project administration, data acquisition, qualitative analysis, manuscript commenting.  
31

32  
33 **Julie Parkes**, (<https://orcid.org/0000-0002-6490-395X>) (Professor in Public Health) was the Chief  
34  
35 Investigator, and contributed to the conceptualisation and design, funding acquisition, protocol  
36  
37 development, trial conduct, manuscript commenting.  
38

### 39 **Acknowledgements**

40  
41  
42 We would like to acknowledge and thank all those who contributed to the study.  
43

44  
45 All the young people who took part in the trial and associated interviews.  
46

47  
48 Gateway Navigators provided by No Limits and Southampton City Council who delivered the  
49  
50 intervention; Debbie Willis, Children and Young People's Services Manager and colleagues at The  
51  
52 Hampton Trust, responsible for LINX; those organisations taking referrals from the Navigators: The  
53  
54 Prince's Trust, Two Saints (Housing) and the Community Mental Health Teams across Hampshire and  
55  
56 Isle of Wight, as well as others. Members of the Trial Management Group (TMG) who contributed at  
57  
58 various stages of the study: Inspector Benjamin Taylor (Hampshire Constabulary), Rosanna Orlando  
59  
60

(Health Economist), Anthony Quinn (Qualitative Researcher), Inspector Stuart Baker (Hampshire Constabulary).

Those who supported the study and funded the intervention: Office of Police and Crime Commissioner (PCC) supporting the PCC for Hampshire and Isle of Wight, and senior management at Hampshire Constabulary

All the police investigators who underwent training and recruited participants into the trial.

Members of the Public Participation Panel (PPP), and all the members of the public who contributed during the development and delivery of the study.

The University of Southampton for being the study sponsor and to members of the Study Steering and Data Monitoring and Ethics Committee for their advice and support.

## References

1. Alcorn T. Rethinking mental health care for young offenders. *The Lancet*. 2014;383(9925):1283-4.
2. Underwood LA, Washington A. Mental Illness and Juvenile Offenders. *International Journal of Environmental Research and Public Health*. 2016;13(2):228.
3. Lauren Bennett BB, Rose Dowling and Tracy Shildrick. *Broke, but not broken*. Revolving Doors Agency; 2021.
4. Britton S. *Improving Responses To Young Adults*. In Transition to Adulthood Alliance. UK; 2014.
5. Petrosino A, Turpin-Petrosino C, Guckenberg S. Formal system processing of juveniles: Effects on delinquency. *Campbell Systematic Review* 2010(DOI: 10.4073/csr.2010.1).
6. Weir K, Routledge G, Kilili S. Checkpoint: An innovative programme to navigate people away from the cycle of reoffending: Implementation phase evaluation. *Policing: A Journal of Policy and Practice*. 2021;15(1):508-27.
7. Neyroud P. *Out of court disposals managed by the police: a review of the evidence*. Commissioned by the National Police Chief's Council of England and Wales University of Cambridge. 2018.
8. Britton S. *PCC spotlight: Young Adults (18-24) in contact with police and criminal justice services*. UK; 2015.
9. Neyroud P, Slothower M. *Operation Turning Point: interim report on a randomised trial in Birmingham, UK*. Cambridge; 2013.
10. Wilson DB, Brennan I, Olaghery A. Police-initiated diversion for youth to prevent future delinquent behavior: A systematic review. *Campbell Systematic Reviews*. 2018;14(1):1-88.
11. Cochrane A, Booth A, Walker I, Morgan S, Mitchell A, Barlow-Pay M, et al. Examining the effectiveness of Gateway—an out-of-court community-based intervention to reduce recidivism and improve the health and well-being of young adults committing low-level offences: study protocol for a randomised controlled trial. *Trials*. 2021;22(1):939.

12. Strang H, Sherman L, Ariel B, Chilton S, Braddock R, Rowlinson T, et al. Reducing the Harm of Intimate Partner Violence: Randomized Controlled Trial of the Hampshire Constabulary CARA Experiment. *Camb J Evid Based Polic*. 2017.
13. Stewart-Brown S, K. J. Warwick-Edinburgh Mental Well-being Scale (WEMWBS): User Guide. University of Warwick; 2008.
14. Maheswaran H, Weich S, Powell J, Stewart-Brown S. Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): Group and individual level analysis. *Health and Quality of Life Outcomes*. 2012;10(1):156.
15. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.
16. Lankenau SE, Sanders B, Hathazi D, Bloom JJ. Recruiting and retaining mobile young injection drug users in a longitudinal study. *Subst Use Misuse*. 2010;45(5):684-99.
17. Patel MX, Doku V, Tennakoon L. Challenges in recruitment of research participants. *Advances in Psychiatric Treatment*. 2003;9(3):229-38.
18. Reichardt CS. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. *JSTOR*; 2002.
19. Mitchell O. A Policy Evaluation of Home Detention Sentencing: Evidence from New Zealand: Auckland University of Technology; 2019.
20. Rhodes W, Jalbert SK. Regression discontinuity design in criminal justice evaluation: an introduction and illustration. *Eval Rev*. 2013;37(3-4):239-73.




Figure 1: CONSORT diagram demonstrating the progression of participants through the trial.

481x695mm (38 x 38 DPI)

## Appendix A: Delivery of Gateway and usual process

**Table 1:** Conditions attached to cautions, presented by whether the participant received a Gateway conditional caution or a caution forming part of usual process (either a simple caution or a different conditional caution).

	<b>Gateway conditional caution (n=105)</b>	<b>Usual process (n=80)</b>
<b>Conditions attached (multiple conditions possible), n (%)</b>		
Standard Gateway conditions (no additional conditions added)	85 (81.0)	NA
None (simple caution)	NA	5 (6.3)
Compensation	18 (17.1)	20 (25.0)
Letter of apology	5 (4.8)	10 (12.5)
Victim awareness course	0 (0)	14 (17.5)
Alcohol diversion course	0 (0)	11 (13.8)
Drugs diversion course	0 (0)	16 (20.0)
Not to enter specific premises	0 (0)	1 (1.3)
Fine	0 (0)	5 (6.3)
Women and Desistance Empowerment programme	0 (0)	9 (11.3)
Restorative justice	0 (0)	0 (0)

**Table 2:** Information on delivery of the Gateway intervention.

	<b>Received Gateway conditional caution (n=105)</b>
<b>LINX workshops attended (supplemented with change of status data)</b>	
<b>Number with data, n (%)</b>	<b>101 (96.2)</b>
0 (Did not attend LINX sessions due to COVID-19 pause)	4 (4.0)
0 (participant chose to not attend LINX sessions)	8 (7.9)
1 (participant chose not to attend LINX session)	1 (1.0)
2	88 (87.1)
<b>Delivery of LINX workshops</b>	
<b>Number with data, n (% of those who attended at least one workshop)</b>	<b>80 (89.9%)</b>



Face-to-face	45 (56.3)
Telephone	35 (43.8)
<b>Contacts attempted by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	52.8 (25.0)
Median (IQR)	42 (39, 63)
Min, Max	22, 168
<b>Successful contacts made by navigator (excluding LINX workshops)</b>	
<b>Number with data, n (%)</b>	<b>76 (72.4)</b>
Mean (SD)	26.0 (20.7)
Median (IQR)	19 (15, 31)
Min, Max	0, 108
<b>Total duration of successful contacts, minutes</b>	
<b>Number with data, n (%)</b>	<b>70 (66.7)</b>
Mean (SD)	761.5 (594.6)
Median (IQR)	626.5 (380, 978)
Min, Max	36, 2785

## Appendix B: Participants informed of their disposal decision after their 4-week follow-up was due

**Table 3:** Information on time between randomisation and disposal decision and whether the 4-week follow-up was attended, for those informed of their disposal decision after the 4-week follow-up was due.

	<b>Gateway conditional caution (n=12)</b>	<b>Usual process (n=3)</b>	<b>Total (n=15)</b>
<b>Time between randomisation and disposal, days</b>			
<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>
Mean (SD)	49.6 (18.1)	NA	NA
Median (IQR)	42 (34.5, 67.5)	NA	NA
Min, Max	29, 77	NA	NA
<b>Attended 4-week follow-up, n (%)</b>			
<b>Number with data (%)</b>	<b>12 (100)</b>	<b>3 (100)</b>	<b>15 (100)</b>

Yes	8 (66.7)	NA	NA
No	4 (33.3)	NA	NA

## Appendix C: Index of Multiple Drug Use

**Table 4:** Index of Multiple Drug Use presented at 4-weeks, 16-weeks and 1-year post randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Week 4</b>		
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>
Mean (SD)	23.3 (6.4)	21.3 (5.0)
Median (IQR)	22 (18, 27)	21.5 (16.5, 25)
Min, Max	15, 42	15, 31
<b>Week 16</b>		
<b>Number with data, n (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	23.3 (7.5)	22.3 (5.9)
Median (IQR)	21 (17, 27)	22 (16, 25)
Min, Max	15, 47	15, 38
<b>Year 1</b>		
<b>Number with data, n (%)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Mean (SD)	25.2 (7.7)	25.8 (6.3)
Median (IQR)	23 (18, 31)	25.5 (21, 28.5)
Min, Max	16, 41	16, 38

## Appendix D: Adverse childhood experiences

**Table 5:** Adverse childhood experiences reported at 16 weeks post-randomisation.

	<b>Gateway conditional caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Number of adverse childhood experiences</b>		
<b>Number with data (%)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>
Mean (SD)	3.0 (2.6)	3.6 (3.0)
Median (IQR)	2 (1, 5)	4 (1, 5)
Min, Max	0, 10	0, 11

## Appendix E: Health economic analysis

**Table 6:** Health economic data at 4-weeks, 16-weeks and 1-year post-randomisation, presented by group.

	<b>4-weeks post-randomisation</b>	<b>16-weeks post-randomisation</b>	<b>1-year post-randomisation</b>

	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>	<b>Gateway condition al caution (n=109)</b>	<b>Usual process (n=82)</b>
<b>Employed in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>16 (19.5)</b>
Yes	31 (54.4)	16 (44.4)	31 (57.4)	19 (48.7)	16 (59.3)	11 (68.8)
No	26 (45.6)	20 (55.6)	23 (42.6)	20 (51.3)	11 (40.7)	5 (31.3)
<b>Number of times visited GP in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.4 (0.7)	0.5 (1.0)	0.4 (1.0)	0.5 (0.9)	0.5 (1.0)	1.3 (2.6)
Median (IQR)	0 (0, 1)	0 (0, 0.5)	0 (0, 0)	0 (0, 0)	0 (0, 1)	1 (0, 1)
Min, Max	0, 3	0, 4	0, 5	0, 3	0, 4	0, 10
<b>Number of times used drug/alcohol services in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.3 (0.9)	0.3 (1.7)	0.4 (1.2)	0.1 (0.4)	0.2 (0.8)	0.4 (1.1)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 10	0, 5	0, 2	0, 4	0, 4
<b>Number of times visited accident and emergency in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.9)	0.1 (0.2)	0.1 (0.3)	0 (0.2)	0.6 (1.9)	0.2 (0.6)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 6	0, 1	0, 2	0, 1	0, 10	0, 2
<b>Number of times admitted to hospital as inpatient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0.1 (0.3)	0 (0)	0.1 (0.3)	0 (0)	0.3 (1.0)	0 (0)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 2	0, 0	0, 2	0, 0	0, 4	0, 0
<b>Number of times used community mental health</b>						

<b>team in previous month</b>						
<b>Number with data, n (%)</b>	<b>56 (51.4)</b>	<b>35 (2.7)</b>	<b>53 (48.6)</b>	<b>38 (46.3)</b>	<b>26 (23.9)</b>	<b>15 (18.3)</b>
Mean (SD)	0.2 (0.8)	0.2 (0.7)	0.2 (0.6)	1.1 (4.9)	0.4 (1.1)	0.5 (1.2)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 4	0, 3	0, 3	0, 30	0, 4	0, 4
<b>Number of times used psychiatric services as in-patient in previous month</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>53 (48.6)</b>	<b>39 (47.6)</b>	<b>27 (24.8)</b>	<b>15 (18.3)</b>
Mean (SD)	0 (0.2)	0 (0.2)	0 (0)	0.2 (1.0)	0 (0.2)	0.1 (0.3)
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Min, Max	0, 1	0, 1	0, 0	0, 6	0, 1	0, 1
<b>Used the following prescribed medications in previous month, n (%)</b>						
<b>Number with data, n (%)</b>	<b>57 (52.3)</b>	<b>36 (43.9)</b>	<b>54 (49.5)</b>	<b>39 (47.6)</b>	<b>27 (25.0)</b>	<b>16 (19.3)</b>
Amitriptyline	1 (1.8)	0 (0)	1 (1.9)	0 (0)	2 (7.4)	0 (0)
Aripirazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cerelle	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Citalopram	3 (5.3)	1 (2.8)	1 (1.9)	2 (5.1)	1 (3.7)	0 (0)
Co-codamol	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Codeine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Cyclizine	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Diazepam	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Doxycycline	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Inhaler	0 (0)	4 (11.1)	5 (9.3)	2 (5.1)	1 (3.7)	0 (0)
Escitalopram	1 (1.8)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Fluoxetine	3 (5.3)	1 (2.8)	0 (0)	2 (5.1)	0 (0)	0 (0)
Quetiapine	2 (3.5)	1 (2.8)	0 (0)	0 (0)	0 (0)	1 (6.3)
Lamotrigine	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.7)	0 (0)
Lymecycline	0 (0)	2 (5.6)	0 (0)	1 (2.6)	0 (0)	0 (0)
Macrogol 3350	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Melatonin	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Methadone	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Mirtazapine	2 (3.5)	0 (0)	2 (3.7)	0 (0)	1 (3.7)	1 (6.3)
Naproxen	1 (1.8)	0 (0)	2 (3.7)	0 (0)	0 (0)	0 (0)
Omeprazole	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ondansetron	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Olanzapine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Phenergan	0 (0)	2 (5.6)	0 (0)	0 (0)	0 (0)	0 (0)

Prednisolone	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Pregabalin	0 (0)	1 (2.8)	1 (1.9)	0 (0)	0 (0)	0 (0)
Prochlorperazine maleate	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Promethazine hydrochloride	0 (0)	0 (0)	0 (0)	1 (2.6)	0 (0)	0 (0)
Propranolol hydrochloride	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Quetiapine	2 (3.5)	0 (0)	4 (7.4)	3 (7.7)	2 (7.4)	0 (0)
Ramipril	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Risperidone	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
Salbutamol	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6.3)
Sertraline	3 (5.3)	4 (11.1)	7 (13.0)	5 (12.8)	2 (7.4)	2 (12.5)
Prochlorperazine	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)	0 (0)
Tacrolimus	1 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Venlafaxine	1 (1.8)	0 (0)	0 (0)	1 (2.6)	1 (3.7)	0 (0)
Vortioxetine	0 (0)	1 (2.8)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Reason for using prescribed medications in previous month, n (%)</b>						
<b>Number with data (% of those who reported using a medication)</b>						
Acne	0 (0)	3 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)
Anterior cruciate ligament injury	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
ADHD	1 (5.0)	1 (6.7)	1 (4.8)	0 (0)	0 (0)	0 (0)
Anxiety	7 (35.0)	7 (46.7)	4 (19.0)	2 (14.3)	2 (25.0)	2 (28.6)
Asthma	1 (5.0)	4 (26.7)	5 (23.8)	2 (14.3)	1 (12.5)	1 (14.3)
Back pain	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Blood pressure	0 (0)	0 (0)	0 (0)	0 (0)	1 (12.5)	0 (0)
Depression	11 (55.0)	7 (46.7)	8 (38.1)	3 (21.4)	5 (62.5)	2 (28.6)
Ear infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Gastroparesis	1 (5.0)	0 (0)	1 (4.8)	0 (0)	1 (12.5)	0 (0)
Heroin addiction	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Hypertension	0 (0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Immune	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)

system						
suppression						
post-kidney						
transplant						
Inflammation	1 (5.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Insomnia	2 (10.0)	1 (6.7)	0 (0)	1 (7.1)	1 (12.5)	0 (0)
Mood	2 (10.0)	1 (6.7)	3 (14.3)	1 (7.1)	1 (12.5)	0 (0)
stabilisation						
Nail infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (14.3)
Nausea	1 (5.0)	0 (0)	1 (4.8)	0 (0)	0 (0)	0 (0)
Pain relief	0 (0)	0 (0)	2 (9.5)	0 (0)	1 (12.5)	0 (0)
Panic attacks	0 (0)	1 (6.7)	0 (0)	0 (0)	0 (0)	0 (0)
Psychosis	2 (10.0)	1 (6.7)	1 (4.8)	0 (0)	1 (12.5)	1 (14.3)
PTSD	0 (0)	2 (13.3)	0 (0)	0 (0)	0 (0)	0 (0)



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	4
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	2, 5, 7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	8, 9
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7, 8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9, 10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10, 11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	10, 11
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12 and Figure 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	12 and Figure 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	2, 12
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	13, 14
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	10, 16, 17, 18
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	16, 17, 18
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	15, 18, 19
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20, 21
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	19, 20, 21
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	19, 20, 21
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	3
Protocol	24	Where the full trial protocol can be accessed, if available	5
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	22

Citation: Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine. 2010;8:18. © 2010 Schulz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).